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ABSTRACT
In the past three decades, many studies employing hollow-fiber liquid-phase microextraction 
(HF-LPME) bioanalytical methods have been published. This type of extraction method 
presents many advantages over classical techniques, such as high preconcentration factor, 
clean extracts, and a green chemistry approach. The basic mechanism of extraction relies 
on the migration of the analytes through a liquid membrane sustained in the pores of the 
walls of a porous hollow fiber, and from there into an acceptor phase present in the lumen of 
the fiber. This acceptor phase can be injected directly onto the instrument used for analysis. 
The mass transfer occurs by passive diffusion and it can be enhanced by using a carrier or 
applying an electrical potential across the phases. Due to its advantages, and considering 
that no study systematically compiled the characteristics of the published methods in one 
single accessible source of information, the aim of this systematic review is to assess the 
data regarding bioanalytical methods, compile, and analyse the studies published until up to 
October of 2017. The data source used for the systematic review were Pubmed, Web of 
Science, and Science Direct, and 171 studies were included in the final review by two 
independent reviewers, resulting in a reliable and accessible source of information about 
bioanalytical methods employing HF-LPME. 
KEYWORDS
Hollow-fiber liquid-phase microextraction, bioanalysis, forensic toxicology, sample 
preparation, green chemistry
1. INTRODUCTION
Sample preparation is a fundamental step in analytical chemistry, especially when the 
analytes are contained within complex matrices. The main purpose of this step is to simplify 
the matrix, enrich the analyte in the extract and clean-up the sample [1]. The extraction is an 
equilibrium-based process related to the distribution of a solute or solutes between two 
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phases [2]. It is an essential step for many forensic toxicological analyses, which are 
normally related to complex biological matrices and low analyte concentrations [3, 4].
The most popular extraction methods are liquid-liquid extraction (LLE) and solid-phase 
extraction (SPE). However, these two conventional methods have limitations [3-5]. Even 
though LLE is a simple method with the capability of extracting many analytes at once, 
relatively large amounts of solvents are used, emulsions can be formed, and it is not ideal for 
volatile substances, since the extract must be evaporated [1]. SPE was introduced in the late 
1970s and the pre-concentration of the analyte is normally poor and it can be highly time-
consuming and laborious. Benefits of SPE however, include a relatively simple set up and 
clean extracts [3-5]. 
Over the years the scientific community has been trying to work on extraction methods 
requiring fewer steps within the process, and adaptable to field sampling and automation. 
The main purpose of this new arsenal of techniques and products is to provide faster, 
cheaper and cleaner methods for sample preparation. Moreover the scientists are focusing 
on methods with a reduced use of solvents due to the low environmental impact that an ideal 
solvent-free method would have. For that reason many of the methods are being 
miniaturized and presenting solvent-free approach. These methods are called 
microextraction methods [1, 6-8].
One of the microextraction methods is solid-phase microextraction (SPME), which consists 
of using a fiber coated with a sorbent to adsorb the analytes from the sample. This method is 
solvent-free, and gained acceptance and popularity amongst the scientific population, being 
used in many areas, such as forensics, environmental, and clinical. The technique is 
relatively fast and can be automated. Plus, many advances have been made related to 
SPME. On the other hand, this method also possesses drawbacks, such as the high-cost 
and limited lifetime of the fiber, and the carryover effect that may occur [3, 5, 9-11]. 
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There are also the liquid-phase microextraction (LPME) methods that are basically a 
miniaturization of LLE: lower volumes of solvents are employed to extract the analytes from 
the sample, resulting in a reduction of solvent used and the analyst’s exposure to potentially 
toxic substances. Many LPME methods were developed, including SDME, CFME, SBME, 
DLLME, and HF-LPME. These methods overcome many of the drawbacks of the 
aforementioned methods, being both fast and cheap [3, 5]. 
Many reviews have been written about HF-LPME [3, 11-24], but none of them have focused 
on forensic applications of the technique. The present review builds on theoretical and 
practical aspects of the technique, relating them to forensic toxicology. It includes a 
systematic review of the up-to-date bioanalytical methods published using this extraction 
process. It is also an up-to-date compilation of the bioanalytical methods using HF-LPME 
that can be used as a guide for future methods development in the field.
2. PRINCIPLES OF HF-LPME
The mechanism of the extraction using HF-LPME involves the partitioning of the analyte 
between two liquid phases. It depends on the partition coefficient and is influenced by many 
factors, such as: volume ratio between sample and extractor phase, pH of the phases, ionic 
concentration of the phases, extraction time, temperature, and forced convection of the 
system [3]. 
The device used to perform HF-LPME consists of a hollow porous fiber usually made of 
polypropylene (PP) (Figures 1 and 2) which permits the analytes from the sample to pass 
through into the lumen of the fiber, in which the acceptor phase resides. The fiber is 
immersed into the sample, which is aqueous and referred to as the donor phase. Before the 
extraction, the fiber is soaked in an organic solvent to fill its porous wall with the solvent. The 
fiber is then filled with the same organic solvent (2-phase HF-LPME) or with a different (and 
normally aqueous) acceptor solvent (3-phase HF-LPME). One of the ends of the fiber is 
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connected to an apparatus, such as a syringe, to perform the step of introduction of the 
acceptor phase into the lumen of the fiber or its collection from it [13, 14, 16, 17, 25-27].
At a molecular level (Figure 2) the analytes are transferred by passive diffusion from the 
aqueous sample solution to the organic solvent in the walls of the fiber, and afterwards to the 
acceptor solution. The presence of the fiber wall provides some selectivity to the method, as 
it acts as a filter for high-weight molecules and particles, what provides an effective 
separation between the matrix and the analyte. The analytes can become trapped in the 
lumen of the fiber due to the ionization of the molecule (3-phase HF-LPME) or can be 
collected from the organic solution (2-phase HF-LPME). After the extraction, the extract is 
drawn inside a syringe and then injected directly into the analytical instrument, or it can be 
evaporated and reconstituted prior to injection [13, 14, 16, 17, 25-27].
Normally, the 3-phase HF-LPME is used for either basic or acidic analytes with ionisable 
functional groups, such as amines, phenols and carboxylic acids. The extraction, in this 
case, is based on acidic-basic equilibrium. Therefore, for the extraction of analytes with 
basic properties, the pH of the donor phase must be adjusted in an alkaline range, which will 
make the solubilization of the analyte in the aqueous solution more difficult, and will favour 
the transfer of the analytes to the organic phase within the walls of the hollow fiber. The pH 
of the acceptor phase, in this case, should be acidic to facilitate the delivery of the analyte to 
the acceptor phase, as the low pH would result in the analyte being in its ionized form, which 
is soluble in aqueous phases [1, 15, 16, 28-30]. If the injection into the analytical equipment 
is performed directly after the extraction, the 3-phase HF-LPME partially limits the analytical 
method to CE or LC [5].
Due to the disposable nature of the fibers the problem related to carryover present in SPME 
is eliminated. Also due to the capacity of the fiber to efficiently separate the matrix from the 
analyte, it is a good way of decreasing the matrix effects, and providing the cleaning-up of 
the samples, making it possible to use the extraction technique in complex matrices [20]. 
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Moreover the ratio between the volumes of the donor and acceptor phases in HF-LPME is 
very high, making the enrichment factor of HF-LPME high [12, 31]. Besides that, this 
extraction method gives a high selectivity, is relatively simple, cheap, and is linked to green 
chemistry [7, 11, 12, 17]. Another advantage is that the technique combines extraction and 
concentration in one step, something that is not possible with other methods, such as LLE 
and SPE. On the other hand, it is usually not an exhaustive method and may present poor 
reproducibility due to manual cutting and sealing of the membrane [20].
3. PARAMETERS AFFECTING THE HF-LPME
During the development of a HF-LPME method some parameters can be optimized in order 
to obtain the best results. Some of these parameters are described below.
3.1 Solvent
To perform an efficient extraction, the solvent must present a good selectivity and a high 
partition coefficient related to the analyte to be extracted [6, 12, 15, 32]. The solvent can be 
chosen by the principle of like-dissolves-like. Most non-polar solvents (e.g. aliphatic or 
aromatic hydrocarbons) will efficiently extract most of the analytes via interaction through 
dispersion forces and hydrophobic effect. Solvents that present functional groups such as 
alcohol, ketone and halide may be used to increase the ability to interact through dipole-
dipole or hydrogen-bonding interactions, increasing the extraction of more polar analytes. 
Therefore the choice of the solvent also depends on the characteristics of the analytes [1].
The viscosity is also an important parameter: the solvent must present an adequate viscosity 
to avoid leaking out of the fiber, however it cannot be too viscous to allow the diffusion of the 
analytes, improving the kinetics of the mass transfer [1, 12, 15, 32].
The loss of solvent due to evaporation and solubilization must also be taken into account. 
The loss of solvent can have a significant impact in HF-LPME due to the low volume of 
solvent used in the process (few microliters) [1, 12, 15, 32]. 
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One important aspect of HF-LPME is the possibility of extracting and concentrating the 
analytes simultaneously, and therefore, choosing the optimal solvent is crucial. For example, 
1-octanol is not directly compatible with the LC mobile phase, and needs to be evaporated 
and replaced by an adequate LC solvent prior to the injection if it is used as the acceptor 
phase. For GC, the extraction solvent must not co-elute with the analyte peaks, therefore 
they must present different boiling points [1].
The most common solvent used for LPME methods, including the HF-LPME, is 1-octanol. 
Many other solvents have been used, such as: toluene, tetrachloroethene, o-xylene, decane, 
1-undecanol, dihexyl ether, n-hexane, undecane, and cyclohexane. Alkanes are generally 
not good as they cannot dissolve many of the analytes due to the absence of polar moieties 
[1]. 
3.2 pH of donor and acceptor phases
The effect of the pH has been discussed previously. Depending on the nature of the analyte 
(acidic or basic), the pH of the donor phase should be ideal to keep the molecules in the 
non-ionized form. In this form, the molecules are more soluble in organic solvents, 
increasing the migration of the analyte to the organic phase within the walls of the fiber. In 
case the system is a 3-phase, composed of another aqueous solution as the acceptor 
phase, the pH of that phase should be within a pH range that would keep the analytes in 
their ionized form, avoiding them being back-extracted to the organic solvent, and trapping 
them in the lumen of the fiber. 
3.3 Ionic strength
Higher ionic strength (salt concentration) usually decreases the solubility of the molecules in 
aqueous solutions, and enhances the efficiency of the extraction. However, this effect is non-
predictable and can be the opposite. The increase of the ionic strength of the aqueous 
solution also helps to decrease the solubility of organic solvents in it, diminishing the loss of 
solvent due to solubilization in the sample. On the other hand, the opposite effect of the 
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addition of salt into the aqueous phase may happen due to the modification of the physical-
chemical properties of the transition film present in the interface “donor phase-organic 
solvent” [1, 20]. 
This effect is called the salting-out effect and it varies with the type of salt employed 
(normally NaCl or Na2SO4) and, to a lesser extent, with the structure of the analyte. The 
difference in the propensity of the salt to cause salting-out is related to different 
characteristics of the ions (structure, size, charge density, hydration, and dielectric constant). 
It is important to highlight that the salting-out effect is an entirely physical phenomenon and 
does not affect properties of analytes or other molecules [1, 20, 33]. 
3.4 Extraction time
The process of extraction in systems with liquid-liquid equilibria involves the partioning 
between two liquid phases that are dynamically exchanging their contents between each 
other. Mass transfer is time-dependent and normally increases along with extraction. The 
HF-LPME methods normally do not run until it reaches the equilibrium as otherwise the 
extraction time would be too long, and part of the small amount of solvent would be lost 
during the process [20].  As equilibrium is normally not reached, extraction time is an 
important factor to be optimized, and the amount of analyte extracted will be dependent on 
the time expended in the extraction process.
3.5 Extraction temperature
Temperature is another factor that influences diffusion and constant of equilibrium of the 
species, resulting in a decrease in the time expended to reach the equilibrium. On the other 
hand, the water-organic solvent partitioning of most compounds is only weakly dependent on 
temperature, which means that temperature has little influence on the constant of equilibrium 
between liquid phases. However, it plays an important role when it comes to extraction 
involving water-gas or gas-solvent equilibria, e.g. headspace HF-LPME [1].
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Even though higher temperatures can favour faster achievement of thermodynamic 
equilibrium, the increase of the temperature can cause evaporation of the solvent 
impregnated in the walls of the fiber, leading to loss of solvent [20].
3.6 Forced convection
Another important factor influencing distribution ratio is the mechanical energy input into the 
system. The molecules in solution undergo random motion, with constant changing speed 
and directions due to collisions and interactions with solvent molecules. The rate of transport 
of the molecules of analytes from one phase to another depends, at a molecular level, on 
this random molecular motion or diffusion. This diffusion is governed also by temperature of 
the system, viscosity of the environment, and size of the diffusing molecule. The convection 
process, normally done by stirring or agitation, is important as it enhances molecular 
diffusion, thus increasing the mass transfer between phases [1, 2]. 
Even though thermodynamic equilibrium time is inversely proportional to the mechanical 
energy submitted over the system, excess of agitation can cause the formation of bubbles 
on the surface of the fiber, decreasing the contact between the organic solvent and the 
analytes present in the donor phase. It also can cause evaporation of the organic solvent to 
be increased. Thus, optimum agitation intensity must be employed [34-37].
3.7 Use of a carrier or difference of voltage
HF-LPME is more efficient to extract analytes of low or moderate polarity. When it comes to 
the extraction of high polarity molecules, extraction efficiency cannot rely only on the 
partition coefficient of the analytes. In these cases, the experimentalist can use tools, such 
as the already cited acid-base speciation, and molecular pairing or application of an 
electrical field (EME). Another common solution is the adoption of pre-steps, such as 
derivatization [1].
The pairing molecule (aka carrier or surfactants) are amphiphilic molecules with a polar or 
ionic group and a hydrophobic group [38]. By converting the analyte in chemical species with 
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higher partition coefficient than the original compound, the pairing-molecule improves the 
analyte extractability. The principle of carrier-mediated membrane transfer is to add an ion-
pair reagent that generates a pair with the target analyte with opposite charge, enabling the 
ion-pairs to possess higher partition coefficients and consequently a higher transfer rate 
between phases (Figure 3) [3, 39, 40].
The application of voltage over HF-LPME was found to increase extraction efficiency, giving 
origin to EME. The extraction takes place in the same device as for the conventional HF-
LPME, apart from the use of a power supply and electrodes to apply the voltage on the 
different compartments of the system (Figure 4). For using difference of voltage instead of 
pH gradient as the driving force, steady state can be reached faster, providing the extraction 
with good recoveries and selectivity [86, 88, 117, 147][85, 94].
4. REVIEW OF THE APPLICATION OF HF-LPME TO BIOANALYTICAL METHODS – A 
SYSTEMATIC APPROACH
4.1 Method
A review was completed to summarize the bioanalytical methods developed applying HF-
LPME. For this purpose, the search covered three literature databases (Pubmed, Web of 
Science, and Science Direct) using the following search term: “microextraction AND hollow”. 
No search filters were used, except for Science Direct (in which we restricted the descriptors 
for the title, keywords and abstract only). The snowballing technique was also employed in 
the search of articles of interest. The aim was to carry out a wide literature search. All 
articles containing bioanalytical methods (analysis of any xenobiotic and biotics in biological 
systems) were included in the first step of the review. No exclusion criteria concerning the 
date of the publication were applied (the search was performed for relevant studies up to 
October of 2017). The exclusion criteria applied to reduce the initial pool of found articles to 
a final amount of articles that were included in the systematic review is summarized in Table 
1 below.
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Language of publication is not EnglishCriteria related to 
the publication Article was not available as full-text
Not HF-LPMECriteria related to 
the extraction 
method Dynamic HF-LPME
Review article
Pharmacokinetic study
Protein-binding investigation
Criteria related to 
the purpose of the 
study
Octanol/water distribution investigation
Analysis of environmental samples (e.g. water, soil)
Analysis of food (e.g. vegetables, milk)Criteria related to the sample Biological sample not from human source (e.g. rat blood)
Analysis of metals and related compounds (e.g. organometallics)
Analysis of compounds from the environmental exposure (e.g. 
substances from pollution of air or water)
Analysis of compounds from dietary exposure (e.g. nitrites, 
preservatives)
Endogenous substances with no forensic interest (e.g. 
angiotensin, vitamins, hormones, non-exposure biomarkers)
Criteria related to 
the analyte
Other substances with no forensic interest (e.g. cosmetics)
Table 1. Exclusion criteria applied to the review.
Studies with a different main purpose than developing methods using HF-LPME (such as 
protein-binding investigation) were included if they involved the development of a new HF-
LPME method. Articles not available as full-text were attempted to be accessed by 
alternative sources before being excluded, such as inter-institutional request, author e-
mailing, and search using other databases or Google.
Dynamic HF-LPME studies were excluded based on the different kinetics and dynamics of 
the system, as fresh solvent or sample is constantly introduced during the extraction in this 
technique.
Two reviewers independently completed the review, searching and compiling the articles. 
After this, they extracted the data from the articles in pre-defined tables. In case of difference 
between the data extracted by the reviewers, the discordant data were discussed, and 
agreement reached before data was adopted. 
All of the data of interest was extracted, compiled (Tables 2 and 3) and discussed below.
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4.2 Results
In the first step of the systematic review, 1002 potentially relevant articles were identified, of 
which 643 were excluded by simply reading the article title or abstract. From the remaining, 
359 articles were evaluated and 188 articles were excluded upon reading the full text. The 
data of interest from the remaining 171 articles were compiled (Figure 5) in Tables 2 and 3 
and discussed. Some articles presented more than one HF-LPME method.
4.3 Forensic Toxicological Applications of HF-LPME
Forensic toxicology plays an important role within the forensic sciences, and society has 
increasingly higher expectations of what forensic scientists in general can achieve. This is 
mainly due to the so-called “CSI-effect”, but with the increasing number of cases related to 
NPS, forensic toxicologists are under considerable pressure to test for an increasing range 
of drugs in smaller and smaller specimen volumes [41-43]. Besides the NPS, several other 
drugs can be detected in biological samples related to legal proceedings, such as ethanol, 
cocaine, benzodiazepines and other sedatives, opiates and LSD and other hallucinogenic 
drugs. A great concern linked to all drugs potentially related to legal proceedings is the high 
heterogeneity between the toxicokinetic and physical-chemical properties of some of them, 
resulting in a challenge for the forensic toxicologists trying to analyse them, including the 
preparation of the samples. Forensic Toxicologists aim to develop sample preparation 
methods that are simple, cheap and efficient, and HF-LPME is an excellent extraction 
method option that has not been extensively explored in the field of forensic toxicology.
Extensive studies of the applicability of HF-LPME in the environmental field has been 
performed [20]. However the number of published studies involving the analysis of drugs in 
biological samples is considerably lower. For applications in forensic toxicology, the number 
of publications is further reduced. Tables 2 and 3 summarize, in chronological order, 
applications of two and three-phase HF-LPME for biological sample analysis, respectively.
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4.4 Two-phase HF-LPME
Forty-one bioanalytical methods that fit into our inclusion criteria have been developed to 
analyse drugs using 2-phase HF-LPME (Table 2); the first study was developed in 2000 by 
Rasmussen et al. [44]. 
Biological matrices
Most of the studies used urine or plasma as matrices (30 and 21 out of 41 respectively) [5, 
44-80]. In post-mortem forensic toxicology the most commonly used biological specimen is 
whole blood, however from all of the 2-phase HF-LPME studies, only 2 used whole blood 
[71, 81]; limited detail was provided regarding the sample preparation in these studies. Two 
articles used oral fluid [75, 82]; one of them [82] developed the method to extract cocaine 
and its metabolites, analytes commonly identified in forensic toxicology casework. The 
detection of drugs of abuse in oral fluid is becoming more common in workplace drug 
testing, and the method developed in this study resulted in a fast and sensitive method (10 
minutes long and limits of detection of 6-28ng/mL by GC-PD-HID). Similar extraction 
conditions were applied to screen urine for the same analytes in another study [46], however 
the extraction time was longer when oral fluid was used, probably due to the lower amount of 
sample available when compared to urine, and the lower concentration of the drugs in oral 
fluid. On the other hand, the method provided higher reproducibility for oral fluid compared 
with urine. Three studies described hair methods utilizing 2-phase HF-LPME [60, 73, 83] but 
the sample preparation was more complex. Some studies mentioned the difference in 
viscosity and protein-binding as reasons for different recoveries when using different 
biological matrices [45, 53]. Most of the studies used the pure biological material or just a 
normal dilution or filtration, with no previous step, however one study [63] used protein 
precipitation in the sample preparation prior to HF-LPME, and demonstrated that this 
approach can be a useful tool for cleaning up the sample and releasing the analytes.
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Ionic strength
Thirty-two out of the 41 publications included studies mentioned to have used ionic strength 
as one of the optimized parameters [5, 45, 49, 51-55, 57-60, 62-70, 72-81, 83]. Eighteen of 
them decided not to use the salting-out technique in the final method [45, 49, 51, 53, 55, 57, 
58, 63, 64, 69, 70, 72-74, 77, 78, 80, 81] due to either the negative impact of increased salt 
concentration on the extraction or the lack of effect of it; and 14 of them [5, 52, 54, 59, 60, 
62, 65-68, 75, 76, 79, 83] decided to use the salting-out effect to improve extraction. All the 
studies that employed the salting-out effect, with exception of three [59, 75, 76], used 
sodium chloride. Meng et al. [75] saturated the donor phase with different salts, and Na2SO4 
presented best results even though the concentrations that were compared were different. 
The concentrations of salt varied from 1% (w/v) to approximately 30% (w/v). Nine of the 41 
studies [44, 46-48, 50, 56, 61, 71, 82] did not mention ionic strength as a parameter to be 
optimized. 
Ion pairing
Ion pairing was used in only four out of the forty-one 2-phase HF-LPME [47, 70, 78, 80] 
studies. Kramer et al. [47] compared two approaches: to extract the analyte (THC 
metabolite) by acidifying the sample, making the analyte neutral, and not using an ion-
pairing agent; or to basify the sample and use an ion-pair agent to form neutral species with 
the ionized analyte. The second approach presented far better results in terms of peak area, 
and therefore was adopted to perform further extractions. According to the authors the 
higher ionic strength of the donor phase due to the ionization of the analyte and due to the 
presence of the ion pairing salt also contributed to less leakage of solvent from the fiber.
Fiber
Most of the 2-phase HF-LPME systems were built using PP fibers with an internal diameter 
of 0.60mm, wall thickness of 200μm, pores of 0.2μm, and 70% porosity. However, some 
studies used PVDF [53, 65, 69, 72] or polyethersulfone fibers [75], or PP fibers with different 
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dimensions [47, 54]. In 2001 [46] a group of researchers employed different fibers to extract 
cocaine and metabolites from urine, and PP presented better performance (larger peak 
areas and more reproducible results) than PVDF. No further information was given about the 
reason for the difference between the results using different fibers. Cui et al. [53] compared 
PP and PVDF fibers, both differing only in wall thickness and porosity. The PVDF fiber 
presented a better solvent compatibility and faster extraction efficiency and operational 
accuracy due to its higher porosity. The thickness of the wall is an important factor that 
influences extraction efficiency and equilibrium time. Another study compared different fibers 
[65], two PVDF and one PP (all with different dimensions), and also attributed the better 
results of the PVDF fiber to its higher porosity. The porosity of the PP fiber was not cited and 
the wall thickness, although is an important parameter, was not explored in this study. An 
overall conclusion is that the dimensions of the fiber impacts on the extraction efficiency; 
solvent permeability and extraction time are highly influenced by the porosity and pore size. 
The wall thickness plays an important role in the equilibrium time (the thicker the wall is, the 
longer it takes for an equilibrium to be reached, as the wall decreases the speed of mass 
transfer between the sample matrices and extraction solvent) [84]. Leinonen et al. [51] 
noticed a wide difference among the extraction efficiency of anabolic steroids (some 
analytes were not extracted at all) between LLE and HF-LPME, and the reason for the 
difference is the high adsorption of the analytes to the PP, therefore the material of which the 
fiber is made is another factor that should be considered in the choice. One of the studies 
used a polyethersulfone home-made fiber for HF-LPME [75], and the recovery results 
presented were very good (recoveries>90%).
Solvent
Different organic solvents were used to impregnate the fiber and as acceptor phase. Most of 
the solvents are long-chain alcohols (1-heptanol, 1-octanol, 1-nonanol, and 1-undecanol). 
Some solvents with high extractability performance are too volatile to be used in a 
microextraction method. An option to overdraw this issue is to use less volatile solvents as 
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co-solvents (approach adopted by Sun et al. [69]). Other studies also used a mixture of 
solvents to extract the analytes [45, 53, 72]. In 2013 [64], a research group used the so-
called supramolecular solvents (see reference for details) for HF-LPME extraction for the 
first time, and it proved to be suitable to substitute organic solvents in 2-phase HF-LPME 
procedures which also reinforces the green chemistry aspect of HF-LPME [17]. 
Derivatization
All studies that used derivatization [47, 54, 74, 75] concluded that in-tube/in-situ 
derivatization - happens within the walls of the fiber during the extraction - can be used 
instead of the traditional derivatization procedure - takes place in a separate vial. Kramer et 
al. [47] compared both derivatization methods and obtained poorer extraction efficiencies 
with in-tube derivatization; the reason is the mild temperature and short time employed by 
the authors, who justified the lower performance stating that the ease and speed of the 
method compensates for this decrease. Liu et al. [54], on the other hand, obtained better 
results for in-situ derivatization, and one of the reasons could be the longer extraction time 
and higher temperature employed in this study.  
Forced convection
All 2-phase HF-LPME were performed under forced convection (stirring, 
shaking/vortexing/vibrating, or ultrasonicating). Around 80% of the articles used stirring with 
a magnetic stir bar to force convection onto the system. Liu et al. [67] introduced 
ultrasonication in the extraction process aiming to enhance the extraction throughput and 
fasten the extraction time by improving mass transfer. They compared the extraction time to 
achieve the equilibrium using stirring or ultrasonication under the same conditions (salt 
concentration, pH, and temperature), and the process using ultrasonication achieved 
equilibrium after 10 minutes, whilst the system using stirring reached equilibrium after 30 
minutes. However, the use of ultrasound irradiation must be carefully evaluated due to the 
possibility of damaging the fiber [53].
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Extraction time
Most of the extraction processes were between 10 and 30 minutes (17 studies) or 30 to 60 
minutes (16 studies). One study [82] aimed to develop a rapid screening test for cocaine and 
metabolites in urine, therefore employing a short extraction time (3 minutes). On the other 
hand, some studies had a long extraction time (equal or higher than 60 minutes) aiming to 
achieve exhaustion and avoid having a kinetic method [50, 65, 68, 70, 80]. 
Temperature
Few studies adopted extraction temperature as an optimizable parameter. Most of them 
performed the extraction at room temperature. Few studies adopted temperature higher than 
30oC after optimization [52, 54-56, 59, 60, 62, 67, 74, 76]. Most of these studies justified the 
positive effect of temperature on the extraction based on kinetics and thermodynamics of 
mass transfer; only three studies [54], [74] and [56] justified the higher extraction efficiencies 
under higher temperature based on the improvement of derivatization and hydrolysis 
efficiencies respectively.
Electromembrane extraction
Only two 2-phase HF-LPME studies [61, 73] used EME. EME was first used in 2006, and it 
is widely employed in 3-phase systems in which both the donor and acceptor phases are 
normally aqueous. The solvents must present some important characteristics in EME, such 
as good electrical permittivity and potential to dissolve ionic species. Daravani et al. [61] 
compared the EME of a model analyte in 2- and 3-phase HF-LPME, and concluded that the 
2-phase HF-LPME proved faster and simpler. By using a combination of EME and 2-phase 
HF-LPME, they concluded that mainly electrokinetic migration was responsible for the 
extraction, and not simple passive diffusion, as the equilibrium was achieved in a short 
period of time. 
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Analytical method
The analytical instrumentation systems employed for separation and detection or 
quantification of the analytes were very variable (GC, LC, CE and ULC with NPD, PD-HID, 
FID, UV, MS, MS/MS, FPD, ECD or FD). For the 2-phase HF-LPME, GC was the most used 
technique for separation due to the nature of the acceptor phase being organic. Some of the 
studies that used LC or ULC [49, 51, 74] for separation had to dry the extracts and 
reconstitute them with the appropriate solvent before injecting onto the instrument. Other 
used a small injection volume (5µL or 10µL) not to disturb the chemical equilibrium between 
the mobile phase and the analyte [52, 69, 76]. Five studies [59, 68, 70, 77, 80] did not adopt 
any of these approaches but still obtained good results from the LC-FD and LC-UV. The 
study that used supramolecular solvent also injected a relatively high volume (20µL) of 
extract onto the LC-UV [64]. One study [65] took 10µL of the acceptor phase (1-octanol), 
and diluted with 300µL of methanol before the injection onto the LC. 
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Ref. Analytes Matrix
Donor phase:
Volume
pH
Additives
Fiber:
Material
Length
id(mm)xwt(mm)xps(µm)
Solvent and Additives Acceptor phase and Additives Extraction process Instrumentation
[44] DiazepamPrazepam
U
P
1.5mL
pH 5.5
PP
4cm
0.6x0.2x0.2
1-octanol 1-octanol
Vibrating
1000rpm
30min
GC-NPD
[45] DiazepamNDMD
U
P
3.5 (U); 3.0mL (P)
pH 7.5
No salt added
PP
6cm
0.6x0.2x0.2
Butyl acetate:1-octanol (1:1 v/v) (U)
Dihexyl ether:1-octanol (1:3 v/v) (P)
Butyl acetate:1-octanol (1:1 v/v) 
(U)
Hexyl ether:1-octanol (1:3 v/v) (P)
Vibrating
600rpm
50min
GC-NPD
[46]
Cocaine
Cocaethylene
EMeE
AEME
U 8mLpH 10.6
PP
6cm
0.6x0.2x0.2
Chloroform Chloroform
Stirring
1600rpm
3min
GC-PDHID
[47] THC-COOH U
8mL
pH 8
Bu4N+-HSO4
PP
6cm
0.6x0.2x0.64
Octane:BSTFA (1:5 v/v) Octane:BSTFA (1:5 v/v)
Stirring
1540rpm
Room T
8min
GC-PDHID
[82]
Cocaine
Cocaethylene
EMeE
AEME
OF 2.2mLpH 10.5
PP
7cm
0.6x0.2x0.2
Chlorophorm Chlorophorm
Stirring
2000rpm
10min
GC-PDHID
[48]
Methadone
Promethazine
Haloperidol
U
P
4mL
pH 13.1
PP
8cm
0.6x0.2x0.2
Dihexyl ether Dihexyl ether
Vibrating
1500rpm
45min
GC-FID
[49] Mirtazapine P
4mL
pH 13.6
No salt added
PP
7cm
0.6x0.2x0.2
Toluene Toluene
Stirring
30min
ca. 22oC
LC-UV
[50] Basic drugs P pH 7
PP
6.5cm
0.6x0.2x0.2
1-octanol 1-octanol
Vibrating
1500rpm
60min
CE-UV
[51] Anabolic steroids U
4mL
pH 7
No salt added
PP
6cm
0.6xn.r.x0.2
1-octanol 1-octanol
Stirring
1250rpm
Room T
45min
LC-MS
[52]
Thiazide diuretics
Clopamide
Probenecid
Loop diuretics
U
7.5mL
pH 2
15% (w/v) NaCl
PP
8cm
0.6x0.2x0.2
1-octanol 1-octanol
Stirring
1010rpm
40oC
40min
LC-MS/MS
[53] Flunitrazepam PU
4mL
pH 9.5 (U); 8.0 (P)
No salt added
PVDF
1.8cm
1.2x0.2x0.2
p-xylene (U)
p-xylene:1-octanol (3:7 v/v) (P)
p-xylene (U)
p-xylene/1-octanol (3:7 v/v) (P)
Stirring
375 (P); 450 (U) rpm
30oC
30min
GC-MS/MS
[54]
Clenbuterol
Metoprolol
Propranolol
U
5mL
pH 12
14% (w/v) NaCl
PP
1.6cm
0.6x0.2x0.2
Methylbenzol Methylbenzol:MSTFA (1:1 v/v)
Stirring
925rpm
35oC
20min
GC-MS
[75] Free cyanide UOF
5mL
pH 6.5
Saturated with 
Na2SO4
Polyethersulfone
1.5cm
3.75x0.75x0.2
Sodium carbonate + Ni(II)-NH3
Sodium carbonate + Ni(II)-NH3
pH 11
Stirring
900rpm
Room T
10min
CE-UV
[83] THCCBD H
10mg
pH 14
PP
6cm Butyl acetate Butyl acetate
Stirring
600rpm GC-MS/MS
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
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CBN 6.8% (w/v) NaCl 0.6x0.2x0.2 Room T
20min
[55]
Promethazine
Promazine
Chlorpromazine
Trifluoperazine
U
3mL
pH 9
No salt added
PP
1.5cm
0.6x0.2x0.2
Toluene Toluene
Stirring
1000rpm
40oC
10min
GC-FPD
GC-FID
[5]
Amphetamines
Caffeine
Ketamine
U
3mL
pH 12.5
30% (w/v) NaCl
PP
1cm
0.6x0.2x0.2
o-xylene o-xylene
Stirring
1000rpm
Room T (30oC)
20min
GC-FID
[56] Pyrethroid metabolites U
5mL
pH ca. 1
PP
1.5, 2.0, 2.5 and 3.0cm
0.6x0.2x0.2
1-octanol 1-octanol
Stirring
70oC
10min
GC-ECD
[57]
Alfentanil
Fentanyl
Sufentanil
P
U
3mL
pH ca. 11
No salt added
PP
1cm
0.6x0.2x0.2
Dihexyl acetate Dihexyl acetate
Stirring
1000rpm
Room T (25oC)
15min
GC-NPD
[81]
Amitriptyline
Imipramine
Promethazine
B
30µL
pH 11
No salt added
PP
1cm
0.6x0.2x0.2
Toluene Toluene
Stirring
Room T
10min
GC-MS
[58] Tramadol PU
12mL
pH 12
No salt added
PP
1.5cm
n.r.
1-nonanol 1-nonanol
Stirring
1000rpm
Room T
25min
GC-MS
[59] Guaifenesin P
25mL
pH 7.4
1.7% (w/v) K2HPO4
PP
8cm
0.6x0.2x0.2
1-octanol 1-octanol
Stirring
600rpm
37oC
30min
LC-FD
[60] Anabolic steroids UH
20mL
No pH adjustment
7.5% (w/v) NaCl
PP
1.2cm
1.8x0.2x0.2
Toluene Toluene
Stirring
750rpm
40oC
30min
GC-MS
[61]
Imipramine
Desipramine
Citalopram
Sertraline
U 1.2mLNeutral (pH ca. 7)
PP
2.2cm
0.6x0.2x0.2
1-heptanol 1-heptanol
Stirring
1400rpm
60V
15min
GC-MS
[62] SulfetanilAlfentanil
P
U
5mL
pH 10
15% (w/v) NaCl 
PP
1.3cm
0.6x0.2x0.2
1-octanol 1-octanol
Stirring
700rpm
50oC
25min
GC-FID
[63] FluoxetineNorfluoxetine P
5mL
pH 11
No salt added
PP
3.7cm
0.6x0.2x0.2
Dihexyl ether Dihexyl ether
Vibrating
700rpm
30min
GC-MS
[64] Benzodiazepines PU
ca. 5 (P); ca. 25 (U) 
mL
pH ca. 9
No salt added
PP
10cm
0.6x0.2x0.2
Supramolecular solvent Supramolecular solvent
Stirring
900rpm
50min
LC-UV
[65]
Indomethacin
Dexamethasone
Propafenone
P
U
1.8ml
pH 2, 2-8, 10
20% (w/v) NaCl
PVDF
3.5cm
n.r.xn.r.xn.r.
1-octanol 1-octanol
Vibrating
173rpm
Room T
102, 120 and 102min
LC-UV
[66] Methadone PU
10mL
pH 11.5
PP
2cm 1-undecanol 1-undecanol
Stirring
700rpm GC-FID
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5% (w/v) NaCl 0.6x0.2x0.2 20oC
45min
[67] Nicotine P
4.5mL
pH 7.4
29% (w/v) NaCl
n.r.
3cm
n.r.
1-octanol 1-octanol
Sonicating
37oC
10min
GC-FID
[68] Amlodipine U
24mL
pH 10
1.2% (w/v) NaCl 
PP
8.5cm
0.6x0.2x0.2
1-octanol 1-octanol
Stirring
1000rpm
60min
LC-UV
[69]
Naloxone
Buprenorphine
Norbuprenorphine
P
5mL
pH 8.7
No salt added
PVDF
4cm
0.8x0.175x0.16
1-octanol:chlorophorm:toluene 
(2:4:4 v/v/v)
1-octanol:chlorophorm:toluene 
(2:4:4 v/v/v)
Stirring
1000rpm
20oC
30min
ULC-MS
[70] Hydrochlorothiazide U
24mL
pH 12
No salt added
PP
8.5cm
0.6x0.2x0.2
1-octanol  + 2% (w/v) Aliquat 336 1-octanol  + 2% (w/v) Aliquat 336
Stirring
800rpm
90min
LC-UV
[71]
Amphetamines
Methcatinone
Ketamine
Meperidine
Methadone
U
B
8mL
pH 13
PP
4cm
0.6x0.2x0.2
Toluene Toluene
Stirring
500rpm
30oC
15min
GC-MS
[72] Flunitrazepam PU
4mL
pH 9.5 (U); 8.0 (P)
No salt added
PVDF
1.8cm
1.2x0.2x0.2
p-xylene (U)
p-xylene:1-octanol (3:7 v/v) (P)
p-xylene (U)
p-xylene:1-octanol (3:7 v/v) (P)
Stirring
375 (P); 450 (U) rpm
30oC
30min
GC-MS
[73] Metamphetamine HU
4mL
pH 7
No salt added
PP
6cm
0.6x0.2x0.2
1-octanol + 2.5mg/mL grapheme oxide 1-octanol
Stirring
1000rpm
60V
20min
GC-FID
[74] Memantine P
10mL
pH 13
No salt added
PP
8cm
0.6x0.2x0.2
Cyclohexane
Cyclohexane + 0.3mg/mL dansyl 
chloride + 4% (v/v) triethylamine + 
10% (v/v) acetone
Stirring
800rpm
40oC
50min
LC-FD
[76] NaproxenNabumetone
P
U
pH 3
KCl 4% (w/v)
PP
4cm
0.6x0.2x0.2
1-undecanol 1-undecanol
Stirring
600rpm
45oC
20min
LC-FD
[77] AlbendazoleTriclabendazole U
pH 8
No salt added
PP
8.8cm
0.6x0.2x0.2
1-undecanol 1-undecanol
Vortexing
Room T
3min
LC-FD
[79] OxazepamLorazepam
U
P
25mL
No pH adjustment
7.5% (w/v) NaCl
PP
10cm
0.6x0.2x0.2
1-octanol 1-octanol
Stirring
1000rpm
50min
LC-MS
[80] HCTZ U
24mL
pH 12 
No salt added
PP
8.5cm
0.6x0.2x0.2
1-octanol + Aliquat 336 2% (w/w) 1-octanol + Aliquat 336 2% (w/w) Stirring800rpm
90min
LC-UV
[78] Warfarin P
8mL
pH 6.5
No salt added
PP
3cm
0.6x0.2x0.2
1-octanol + CTAB 10mM 1-octanol + CTAB 10mM
Stirring
800rpm
Room T
25min
UV-Vis
Table 2. 2-phase HF-LPME (conventional and variants) of drugs of forensic interest in biological matrices. The concentration values of salt added were converted 
to % (w/v); the pH were calculated based on the concentration of base or acid in some cases. Abbreviations: (A) = acidic; AEME = anhydroecgonine methyl 
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ester; Aliquat-336 = 3-caprylil methyl ammonium chloride; (B) = basic; B = whole blood; BSTFA = bis(trimethylsilyl)trifluoroacetamide; Bu4N+-HSO4= tetra-n-
butylammonium; ca. = approximately; CBD = cannabidiol; CBN = cannabinol; CE = capillary electrophoresis; ECD = electron capture detector; EMeE = ecgonine 
methyl ester; FD = fluorescent detector; FID = flame ionization detector; FPD = flame photometric detector; GC = gas chromatography; H = hair; id = internal 
diameter; K2HPO4 = dipotassium phosphate; LC = high performance liquid chromatography; MS = mass spectrometry; MS/MS = tandem mass spectrometry; 
n.r. = not reported; Na2SO4 = sodium sulfate; NaCl = sodium chloride; NDMD = N-desmethyldiazepam; NPD = nitrogen-phosphorus detector; OF = oral fluid; P 
= plasma; PDHID = pulsed-discharge helium ionization detector-helium ionization detector; PP = polypropylene; ps = pore size; PVDF = polyvinylidene difluoride; 
T = temperature; THC-COOH = 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid; THC = Δ9-tetrahydrocannabinol; wt = wall thickness; U = urine; ULC = ultra-
high performance liquid chromatography; UV = ultra-violet
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4.5 Three-phase HF-LPME
One hundred and forty-two bioanalytical methods were described in 136 publications fit into 
the inclusion criteria (Table 3).
Biological matrices
Similarly to 2-phase HF-LPME, most of the 3-phase HF-LPME methods included in the 
systematic review used plasma (92 out of 142) and/or urine (99 out of 142) as the matrix. 
Few methods used other matrices, such as whole blood [85-92], breast milk [93-96], serum 
[97, 98], oral fluid [99, 100], hair [101], or liver [102].
Halvorsen et al. [85] demonstrated that despite the complexity of whole blood as a matrix the 
recoveries obtained for whole blood and plasma were similar during the extraction of 
methamphetamine and citalopram. However, the time to reach the equilibrium was twice as 
long for whole blood. The same group [86] of researchers tested a screening test for 
amphetamines, and the LOD observed for urine were higher than the LOD observed for 
whole blood due to the high noise present in urine samples. They [87] also evaluated 
qualitatively the matrix effects using the HF-LPME combined with LC-MS for plasma and 
whole blood, and no ion suppression was observed due to the effective sample clean-up in 
HF-LPME. Indeed the HF-LPME provided a good clean-up for the whole blood without any 
complex pre-treatment of the sample in all the studies. Gjelstad et al. [89] showed that the 
dilution of whole blood per se tends to improve the efficiency of the process, making the 
recovery of basic drugs similar to their recovery from plasma. All of the studies used simple 
dilution to deal with whole blood samples. 
Low recoveries (18-38%) previous to any pre-treatment were obtained for breast milk [93] in 
one study, and the authors believe this is due to the rate of drug binding to the sample 
matrix. The authors tested different pre-treatments, and after centrifugation or acidification 
followed by centrifugation the recoveries improved, reaching rates up to 69%. By using EME, 
Kjelsen et al. [94] obtained good recoveries from breast milk (comparable to the recoveries 
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obtained from plasma and urine). The recoveries of levimasole using oral fluid as the 
biological matrix were similar to those obtained from other matrices [100] using EME. 
Comparable recoveries were also obtained for lidocaine and chlorpromazine from serum and 
urine in two studies [97, 98].
One study used hair to analyse amphetamine-type stimulants [101] while another study [102] 
used liver samples to analyse barbiturates, and due to the complexity of dealing with these 
matrices, the sample preparation is more complex and detailed in the articles.
Ionic strength
From the 136 studies, 51 did not optimize ionic strength. Sixty out of the 142 methods [35, 
37, 38, 77, 97, 99, 100, 103-154] decided not to use salt after optimization (some studies 
have more than one method, therefore the number of references can differ from the number 
of methods), and 27 used NaCl with concentrations ranging between 1% to around 30% 
(w/v). One study used KCl for salting-out effect, and 3 studies [75, 155, 156] used Na2SO4 at 
different concentrations. Two studies compared Na2SO4 with different salts; Lv and cols. 
[155] compared NaCl and Na2SO4 at the same concentrations, and the sulphate presented 
better results, however, because the ionic strength is related to the concentration of all the 
ions in solution, Na2SO4 is ionically stronger when in solution, and comparing both salts in 
the same concentration is not the same as comparing their ionic strength. Moreover this 
study used a carrier and the decreased interaction between the elements of the biological 
sample and the carrier by the use of a salt could be the reason for the increase in extraction 
efficiency.
Ion pairing
The use of ion-pairing agents was present in only 28 methods (27 studies) of the 142 
methods [38-40, 50, 79, 99, 100, 103, 105, 119, 120, 126, 131, 140, 146, 152, 153, 155, 
157-165]. Aiming to correlate solubility and log D data with extraction recoveries, Pedersen-
Bjergaard et al. [50] tried different HF-LPME methods (2-phase HF-LPME and 3-phase HF-
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LPME with and without carrier) to extract drugs with different chemical behaviour. They 
found that those drugs with water solubility values above 150mg/mL and log D<1.8 at pH 13, 
carrier-mediated HF-LPME should be the preferred technique. The same research group 
performed other studies using carrier agents. One of these studies [40] compared different 
organic borates, phosphates, sulphates, and carboxylic acids as pairing agents to extract 
hydrophilic basic drugs; the carriers tested were both water soluble and not, therefore, some 
were solubilized in the donor phase and some of them in the solvent. An important 
conclusion of this study is the demonstration of non-compatibility of some carriers with 
biological samples due to the precipitation of proteins on the surface of the fibers and in the 
donor phase. They also showed that by saturating the biological sample with sodium 
sulphate it is possible to increase the recoveries using a carrier due to the suppression of the 
interactions between the carrier and plasma proteins that this agent provides. Aliquat-336 
was used in approximately one fifth of the 3-phase HF-LPME studies that used a carrier 
agent (6 out of 28), and 10 studies used TEHP, DEHP or both. Combination with EME 
happened in some studies [99, 100, 105, 126, 140, 146, 159, 162, 165]. A recent study [105] 
used C60 fullerene as a carrier agent for the first time. 
Fiber
Most of the articles that described the fibers used in the extraction procedure used PP fibers 
with the conventional parameters already cited; some articles that used PP fibers with other 
dimensions [50, 85, 87-89, 93-96, 130, 151, 154, 166-172] or fibers made of different 
material, such as PVDF [129]. Xi et al. [169] compared fibers made of different materials and 
with different dimensions (PP, PVDF, polysulfone, and polyethersulfone). The PP fiber with 
0.45mm wall thickness and 0.18µm pore size presented the best results. Without any further 
information about porosity percentage and wall thickness of the PVDF, polysulfone and 
polyethersulfone fibers it is not possible to properly correlate the best performance of the PP 
fiber to its dimensions and composition. Halvorsen et al. [85] showed that by changing the 
dimensional parameters of the hollow fibers it is possible to obtain a considerably shorter 
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equilibrium time, mainly when complex biological matrices are used. This happens when the 
contact area is increased and the wall thickness is reduced. As expected, the differences 
between the recoveries were not significant after the equilibrium was reached. 
Solvent
The most common solvent used to impregnate the hollow fiber was 1-octanol (49 studies), 
followed by dihexyl ether (28), NPOE (20), and aliphatic hydrocarbons (16). Other solvents 
consisted of other long-chain aliphatic alcohols, esthers, silicon oil, etc. Some studies aimed 
to develop green bioanalytical methods by testing essential and fixed oils from plants. Four 
studies [40, 102, 167, 173] used plant oils in their extraction method and obtained good 
results, and this reinforces the idea of the green chemistry already at the core of the concept 
of HF-LPME. One of the studies [167] tested different fixed (almond, arachis, olive, and soy-
bean oils) and essential oils (anise, fennel, lavender, and peppermint oils) and compared 
with traditional HF-LPME solvents (dihexyl ether, 1-octanol, and dodecyl acetate) to extract 
the same group of analytes; the results were in general similar between the essential oils 
and the traditional HF-LPME solvents. The fatty oils presented worse results probably due to 
their high viscosity, which lowers the diffusion rate across the organic phase. It was not 
possible to immobilize eucalyptus, lemon, tea tree, clove, and thyme oil, and also oil of 
turpentine in the walls of the fiber. Ho et al. [40] compared the carrier-mediated extraction of 
8 drugs from plasma using peppermint oil or conventional solvents (1-octanol, dihexyl ether, 
NPOE, 2-octanone, dodecyl acetate and silicon oil AR20); seven out of 8 drugs had higher 
extractions using peppermint oil. Menck et al. [102] also tested different fixed and essential 
oils to extract barbiturates from liver samples, and even though eucalyptus oil did not 
present the best results for all the analytes, it was adopted as the best option due to its good 
performance. Eucalyptus oil was also chosen as the best option for extracting ketamine and 
its metabolites from urine in other study [173].
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Derivatization
Four studies used in-situ derivatization during the 3-phase HF-LPME [51, 115, 142, 149]. 
Derivatization played different roles in the included studies, it was used to make a compound 
susceptible to analysis using GC by increasing its volatility [51], to create a chromophore 
making the compound possible to be analysed by UV [115], or just to make the compound 
less hydrophilic to facilitate its migration to the solvent [142, 149]. Also the derivatization took 
place in different places in the system: in the fiber [51], in the DP during the extraction [142, 
149], or in the DP previous to the extraction [115]. The adoption of relatively harsher 
conditions (45oC for 30 minutes) employed by Leinonen et al. during the extraction is based 
on the need of this condition for derivatization. Relatively low recoveries were obtained in 
this study due to the sensitivity of sylilation to the water present in the sample; the authors 
tried to overdraw this by the use of dihexyl ether as the solvent layer membrane to protect 
the reaction that happened in the lumen of the fiber.
Forced convection
Most of the methods used stirring (104) or vibration/vortexing/shaking (25) to force the 
convection of the system. Three studies used sonication for this purpose [90, 102, 174]. Four 
studies did not provide the system with any agitation method [91, 168, 169, 175]. Eibak et al. 
and Jamt et al. tried to simplify the extraction method by not stirring the system; Xi et al. did 
not use any convection method to avoid influencing the drug-protein binding. One study 
used magnetofluid to stir the system [176], and that provided the method with shorter 
extraction time (8 minutes). No study directly compared different agitation methods, and this 
is a potential field to be explored by future researchers.
Extraction time
Regarding the extraction duration, some studies presented short extraction time (equal or 
less than 5 minutes) [77, 91, 94, 130, 168]. Apart from one study [77], all of them used EME, 
what explains why the methods were shorter. Even though two other studies [90, 102] 
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presented relatively short extraction time (5 minutes), time was not an optimized parameter; 
these studies used ultrasonication as a forced convection method. Eibak et al. [168] 
presented for the first time an EME kinetic method, and it was used to effectively quantify 
within 1 minute amitriptyline, citalopram, fluoxetine, and fluvoxamine in human plasma. Song 
at al. [176] developed and validated a method to quantify aristolochic acids in human plasma 
and according to the authors the short extraction time (8 minutes) was due to the use of 
magnetofluid during the magnetic stirring of the samples. Eskandari et al. [122] showed a 
significant extraction time decrease (from 60 to 15 min) by adopting EME instead of the 
conventional HF-LPME. Other studies also compared EME to HF-LPME [122, 159, 175]. 
On the other hand some studies presented a long extraction time (equal or greater than 60 
minutes, reaching up to 5 hours) after optimizing this parameter [68, 70, 80, 88, 103, 110, 
118, 120, 122, 136, 151, 161, 169, 171, 172, 177-179]; other studies adopted long extraction 
times but did not optimize it [40, 50, 93, 157]. Halvorsen et al. [85] showed that by increasing 
the contact surface between the solvent impregnated within the fiber walls and the donor 
and acceptor phases it is possible to decrease the extraction time (in this case by a factor of 
2). Xi et al. [169] adopted a 5-hours extraction method due to the stagnant characteristic of 
the system (the aim of the study was to determine the protein-binding properties of the 
drugs). According to the central composite design by Ebrahimzadeh et al. [180] the 
extraction time did not play an important role in his method, however, they adopted a long 
extraction time to ensure equilibrium was reached. One study presented a total extraction 
time of 60 min [149] but it was a sequential extraction of two drugs with different systems in 
the same vial. Some studies justified the long extraction time based on the complex nature 
of the biological matrices [85, 88].
Temperature
Temperature was optimized in 12 methods [34, 51, 92, 106, 117, 124, 129, 142, 178, 181-
183]. Two of them [51, 142] explained the use of higher temperatures to perform rapid and 
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
28
higher derivatization. The general behaviour of the extraction was the increase of the 
extraction efficiency, and after achieving an optimum temperature, the decrease of the 
efficiency. The main reasons for this could be solvent depletion (due to easier solubilization 
of the solvent in the donor phase at higher temperatures, or due to volatilization), and fiber 
damaging. An important factor to be considered is the Joule effect that can happen during 
the EME, which can increase the temperature of the system.
Electromembrane extraction
Thirty-one methods used EME to perform their extractions [89, 91, 94-96, 99, 100, 105, 122, 
126, 127, 130, 132, 140, 141, 144, 146, 151, 152, 154, 159, 160, 162, 165, 168, 175, 184-
188]. From those, 20 used NPOE as the extraction solvent (with or without a carrier), and 
according to these authors this solvent is already well established as a good option for EME 
for extracting basic compounds; 1-octanol, a traditional solvent for HF-LPME is less likely to 
be used with EME due to the formation of bubbles under high voltage [130]. One of the 
advantages of using EME is that it usually does not require sample pre-treatment [89, 91, 
140, 168, 175]. Some studies showed that the kinetics of the EME can be slower when 
applied to biological matrices, potentially leading to a lower recovery after the same 
extraction time [89, 94, 159, 175, 184]; this is probably due to protein binding and higher 
viscosity of the biological samples. The performance of EME was compared to the 
performance of conventional HF-LPME in some studies [122, 151, 159, 175, 184], and EME 
proved to be faster and more efficient in general. EME showed to be effective even for 
stagnant systems and short extraction times [168, 175]. Daravani et al. [130] were the first to 
try to extract acidic compounds from complex biological matrices using EME. After this study 
other studies included acidic compounds, one of them [140] using 2 fibers in the same 
system to extract basic and acidic substances simultaneously. For that Seidi et al. 
impregnated the different fibers with different solvents that presented optimum extraction for 
both types of drugs. Other studies compared sequential and simultaneous extraction of 
acidic and basic substances, and the sequential option presented better performance [96]. 
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Koruni et al. [146] also used different fibers and different systems to extract acidic and basic 
drugs with a wide range of log P, and for that four systems were used for simultaneous 
extraction. Koruni et al. [146] adopted and interesting approach to analyse basic and acidic 
compounds simultaneously by using a set of two auxiliary electrodes and hollow fibers. 
Eibak et al. [175] used multiple fibers, however, the aim was not to simultaneously extract 
drugs with different properties but to demonstrate how an increase in the SLM contact area 
and acceptor phase volume could impact the extraction efficiency. The objective of the study 
was to achieve exhaustive extraction (recoveries higher than 95%) in a short period of time 
by this geometry optimization of the HF-LPME system, and also to test different extraction 
procedures (by changing volume of donor phase and convection process). Even though they 
succeeded in achieving an exhaustive extraction from water, the same was not observed 
when extracting from plasma, probably due to the protein binding. Moreover, even using the 
3-fibers system, only one out of six drugs were exhaustively extracted after 45 minutes when 
pH difference was used as the driving force and not voltage difference, i. e., conventional 
HF-LPME instead of EME. On the other hand all the drugs were exhaustively extracted after 
10 minutes when EME was employed. 
Analytical method
The analytical systems employed for separation and detection or quantification of the 
analytes in the 3-phase HF-LPME were also very variable. Differently from the 2-phase HF-
LPME, GC was less used, and LC and CE were more employed again due to the aqueous 
nature of the acceptor phase used in this type of HF-LPME. Some of the studies were 
classified as 3-phase HF-LPME for presenting an acceptor phase different from the solvent 
within the walls of the fiber even though both are organic solvents [35, 79, 106, 139, 153, 
163, 189, 190]. Daravani et al. [185] injected the aqueous extract directly onto the GC; 
according to the authors the water phase does not damage bonded and cross-linked 
nonpolar stationary phases, but a strong acid or base does. For that reason neutralization of 
the pH 2 aqueous extract by KOH was performed and glass wool was placed in the injector 
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line to prevent non-volatile compounds originated from the neutralization reaction to reach 
the column. Some other studies [90, 92, 101, 102, 173, 191] dried the aqueous extract 
before reconstituting with an organic solvent to inject directly onto the instrument. All the 
studies that dried the samples and reconstituted them in organic solvent used derivatization 
in this process, except one [92].
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Ref.    Analytes Matrix Donor phase
Fiber:
Material
Length
id(mm)xwt(mm)xps(µm
)
Solvent and Additives Acceptor phase and Additives Extraction process Instrumentation
[107] Methamphetamine UP
2.5mL
pH 13
No salt added
PP
8cm
0.6x0.2x0.2
1-octanol HCl 0.1MpH 1
Stirring
400rpm
45min
CE-UV
[192]
Ibuprofen
Naproxen
Ketoprofen
U 2.5mLpH 1
PP
8cm
0.6x0.2x0.2
Dihexyl ether NaOH 0.01mMpH 12
Vibrating
400rpm
45min
CE-UV
[44]
Metamphetamine 
(CE)
Naproxen (CE)
Citalopram (LC)
NDCIT (LC)
U
P
1-4mL
Variable pH
PP
4 or 8cm
0.6x0.2x0.2
1-octanol
HCl 0.1M (CE)
pH 1; 
NaOH 0.02M (LC)
pH 12.3
Vibrating
1000rpm
45min
CE-UV
LC-FD
[177] CitalopramNDCIT P
4mL
pH ca.13
PP
8cm
0.6x0.2x0.2
Dihexyl ether Phosphate buffer 20mMpH 2.75
Vibrating
1200rpm
60min
CE-UV
[85] MethamphetamineCitalopram
U
P
B
4mL
pH ca.13
PP
8cm
0.6x0.2x0.2
27cm
0.33x0.15x0.4
Dihexyl ether HCl 0.1MpH 1
Vibrating
1500rpm
15min (U, P); 30min (B)
CE-UV
[86] Amphetamines BU
1 (B); 4 (U)mL
pH ca. 13
PP
8cm
0.6x0.2x0.2
Dihexyl ether HCl 0.01MpH 2
Vibrating
1500rpm
15min
FIA-MS/MS
[193] Mianserin P 1mLpH ca. 13.5
PP
8cm
0.6x0.2x0.2
Dihexyl ether HCl 0.01MpH 2
Vibrating
1500rpm
45min
CE-UV
[48]
Methadone
Promethazine
Haloperidol
U
P
4mL
pH 13.1
PP
8cm
0.6x0.2x0.2
Dihexyl ether HCl 10mM
Vibrating
1500rpm
45min
CE-UV
[166] CitalopramDesmethylcitalopram P
1.5mL
pH ca. 13
PP
1.8cm
1.2x0.2x0.2
Dodecyl acetate Phosphate 20mMpH 2.75
Vibrating
1500rpm
45min
CE-UV
[93]
Paroxetine
Fluvoxamine
Mianserin
Citalopram
M 1.5mLpH ca. 13.5
PP
1.8cm
1.2x0.2x0.2
Polyphenyl-methylsiloxane HCl 10mMpH 2
Vibrating
1500rpm
60min
CE-UV
[87] Antidepressant drugs (TCA and SSRI)
P
B
1.5mL
pH 13.1
PP
1.8cm
1.2x0.2x0.2
Dodecyl acetate Formic acid 200mMpH ca. 2
Vibrating
 1500rpm
30min
LC-MS
CE-UV
[39]
Amphetamine
Morphine
Practolol
P
U
4mL
pH 7
Sodium octanoate
PP
8.0cm
0.6x0.2x0.2
1-octanol HCl 50mMpH 1.3
Vibrating
1500rpm
45min
CE-UV
[88] ZolpidemBenzodiazepines B
1.5mL
pH 7.5
PP
1.8cm
1.2x0.2x0.2
Nonanol HCl 0.4MpH 0.4
Vibrating
1500rpm
60min
LC-UV
LC-MS
[167]
Amphetamines
Pethidine
Nortriptyline
Methadone
P
U
1mL
pH ca. 13.5
PP
1.8cm
1.2x0.2x0.2
Plant fatty oils
Plant essential oils
Formic acid 10mM
pH 2.9
Vibrating
1200rpm
45min
CE-UV
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Haloperidol
Loperamide
[157]
Amphetamine
Phenylpropanolamin
e
Cimetidine
Morphine
β-blockers
P
0.1mL
pH 7
Sodium octanoate
PP
6.5cm
0.6x0.2x0.2
1-octanol HCl 50mMpH 1.3
Vibrating
1500rpm
60min
LC-MS
[50] Basic drugs P
1.5mL
pH 13
Sodium octanoate
PP
1.8cm
1.2x0.2x0.2
Dodecyl acetate HCl 10mMpH 2
Vibrating
1500rpm
60min
CE-UV
[40]
Amphetamine
Phenylpropanolamin
e
Metaraminol
Cimetidine
Morphine
β-blockers 
P
0.1mL
pH 7
Bromothymol blue
PP
6.5cm
0.6x0.2x0.2
1-octanol or peppermint oil HCl 50mMpH 1.3
Vibrating
1500rpm
60min
CE-UV
[51] Steroids metabolite U n.r. n.r. Dihexyl ether
MSTFA:ammonium 
iodide:dithioerythritol 
(1000:2:4, v/m/m)
Stirring
1250rpm
45oC
30min
GC-MS
[194]
Imipramine
Amitriptyline
Setraline
P
U
11mL
pH 12
PP
8.8cm
0.6x0.2x0.2
1-dodecane H3PO4 0.1MpH 2.1
Stirring
700rpm
30min
LC-UV
[108] Clenbuterol U
7.5mL
pH 14
No salt added
PP
4.5cm
0.6x0.2x0.2
1-octanol Formic acid 5MpH 1.5
Stirring
1000rpm
30min
LC-UV
LC-MS/MS
[195] Hydroxychloroquine and metabolites U
ca. 4.3mL
pH ca.13
10% (w/v) NaCl
PP
7cm
0.6x0.2x0.2
1-octanol HCl 100mMpH 1
Stirring
1200rpm
Room temperature (ca. 
22oC)
40min
CE-UV
[97] Chlorpromazine USe
11mL
pH 11.8
No salt added
PP
8.8cm
0.6x0.2x0.2
1-dodecane HCl 0.01MpH 2
Stirring
1000rpm
Room temperature
20min
LC-UV
[109] StrychnineBrucine U
4mL
pH ca.13.5
No salt added
PP
8cm
0.6x0.2x0.2
1-octanol H3PO4 100mMpH 1.6
Stirring
1500rpm
Room temperature
40min
CE-UV
[110] TetradrineFangchinoline P
4.5mL
pH 8.5
No salt added
PP
7.5cm
0.6x0.2x0.2
1-octanol HCl 5mMpH 2.3
Stirring
1100rpm
Room temperature (ca. 
22oC)
60 min
LC-UV
[174] Mirtazapine and metabolites P
4mL
pH 8
15% (w/v) NaCl
PP
8cm
0.6x0.2x0.2
Dihexyl ether Acetic acid 0.01MpH 3.4
Sonicating
ca. 35oC
45min
LC-MS
[111] MefloquineCarboxymefloquine P
4mL
pH ca.13.5
No salt added
PP
6.5cm
0.6x0.2x0.2
Dihexyl ether HClO4 10mMpH 2
Stirring
1100rpm
Room temperature (ca. 
23oC)
LC-UV
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30 min
[112] Chloroquine and metabolites P
4mL
pH 11
No salt added
PP
7cm
0.6x0.2x0.2
1-octanol TFA 0.1M
Stirring
1200rpm
Room temperature (ca. 
23oC)
30min
LC-MS/MS
[94]
Pethidine
Nortriptyline
Methadone
Haloperidol
Loperamide
P
U
M
1mL
pH 2
PP
2.5cm
1.2x0.2x0.2
1-isopropyl-4-nitrobenzene pH 2
Vibrating
1000rpm
10V
5min
CE-UV
[196] TCA P 1mLpH 10
PP
3.5cm
0.6x0.2x0.2
Dihexyl Ether
Sodium phosphate 
buffer 50mM
pH 3
Stirring
400rpm
45min
CE-UV
[113]
Furosemide
Bumetanide
Triamterene
U
6mL
pH 1.5 (for acidic)
pH 12.5 (for basic)
No salt added
PP
0.6x0.2x0.2 1-octanol
0.12M NaOH (for acidic)
pH 13.1
0.04M H3PO4 (for basic)
pH 1.9
Stirring
250rpm
Room temperature (ca. 
27oC)
50min
LC-UV
[111] MefloquineCarboxymefloquine P
4mL
pH ca. 12 then pH 
ca. 3
PP
15cm
0.6x0.2x0.2
Dihexyl ether
0.01M perchloric acid 
then 0.05M NaOH
pH 2 and 12.7
Vibrating
1750rpm
30min
LC-UV
[89]
Pethidine
Nortriptyline
Tramadol
Methadone
Haloperidol
Loperamide
P
B 0.5mL
PP
2.5cm
1.2x0.2x0.2
1-ethyl-2-nitrobenzene HCl 10mM
Vibrating
1050rpm
10V
10min
CE-UV
[197] Ibuprofen U 50mLpH 2
PP
27cm
0.6x0.2x0.2
Dihexyl ether NaOHpH 10
Stirring
300rpm
15min
FIA-CL
[198]
Ibuprofen
Diclofenac
Salicylic acid
U 50mLpH 2
PP
27cm
0.6x0.2x0.2
Dihexyl ether pH 12.5
Stirring
300rpm
15min
LC-UV
LC-FD
[158]
Oxytetracycline
Tetracycline
Doxycycline
P 11mLpH ca. 9
PP
8.8cm
0.6x0.2x0.2
1-octanol + 10% (w/v) Aliquat-336 0.1M H3PO4 + 1M NaCl pH 1.6
Stirring
900rpm
35min
LC-UV
[199] Pioglitazone PU
10mL
pH 8
10% (W/v) NaCl
PP
8.8cm
0.6x0.2x0.2
Dihexyl ether HClpH 2.2
Stirring
500rpm
30min
LC-UV
[114] Rosiglitazone PU
10mL
pH 9.5
No salt added
PP
6cm
0.6x0.2x0.2
Dihexyl ether HCl 0.1MpH 1
Stirring
600rpm
30min
CE-UV
LC-UV
[37] FluoxetineNorfluoxetine P
5mL
pH 14
No salt added
PP
7cm
0.6x0.2x0.2
Dihexyl ether HCl 20mMpH 1.7
Stirring
1400rpm
40min
LC-FD
[115] Gabapentin PU
8.5mL
No salt added
FDNB
PP
8.8cm
0.6x0.2x0.2
Dihexyl ether pH 9.1
Stirring
1250rpm
Room temperature
45min
LC-UV
[168]
Amitriptyline
Citalopram
Fluoxetine
P 70µLpH ca. 7.4
PP
2.9cm
1.2x0.2x0.2
1-ethyl-2-nitrobenzene HCOOH 10mMpH 2.9
No forced convection
9V
1min
LC-MS
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Fluvoxamine
[36]
Ketoconazole
Clotrimazole
Miconazole
P
U
10mL
pH 11
NaCl 5% (w/v)
PP
8cm
0.6x0.2x0.2
Dihexyl ether pH 2.5
Stirring
800rpm
45min
LC-UV
[184] Amlodipine PU
3mL
pH 10
PP
8cm
0.6x0.2x0.2
NPOE HCl 10mMpH 2
Stirring
1000rpm
200V
15min
CE-UV
[116] Desipramine PU
8mL
pH 13
No salt added
PP
5cm
0.6x0.2x0.2
Propyl benzoate HCl 1MpH 0
Stirring
700rpm
Room temperature
15min
Voltametry
[117] Phenazopyridine PU
5mL
pH 9
No salt added
PP
3.5cm
0.6x0.2x0.2
Diphenyl ether H2SO4 0.1MpH 1
Stirring
1300rpm
45oC
30min
FIA-DAD
[200] Aristolochic acid U 5mLpH 3
PP
3.3cm
0.6x0.2x0.2
1-octanol NaOH 10mMpH 12
Stirring
800rpm
40min
LC-UV
[178]
Aconitine
Hypaconitine
Mesaconitine
U 5mLpH 11
PP
5.3cm
0.6x0.2x0.2
1-octanol HCl 10mMpH 3
Stirring
800rpm
40oC
60min
LC-UV
[118] MatrineSophocarpine U
4mL
pH 13.7
No salt added
PP
7cm
0.6x0.2x0.2
1-octanol H3PO4 100mMpH 1.5
Stirring
600rpm
60min
LC-UV
[35] ClotrimazoleMiconazole
P
U
24mL
pH 8
No salt added
PP
8cm
0.6x0.2x0.2
1-dodecane Acetonitrile
Stirring
900rpm
40min
GC-FID
[119] Propylthiouracil PU
7.5mL
pH 12
No salt added
PP
8.8cm
0.6x0.2x0.2
1-octanol + 6% (w/v) Aliquat 336 NaClO4 2MpH 9
Stirring
1250rpm
25oC
40min
LC-UV
[120] Dexamethasone PU
7.5mL
pH 3
No salt added
PP
8.8cm
0.6x0.2x0.2
1-octanol + 5% (w/v) Aliquat 336 NaClO4 2MpH 9
Stirring
1250rpm
Room temperature
60min
LC-UV
[121] Desipramine PU
8mL
pH 13
No salt added
PP
5cm
0.6x0.2x0.2
Propyl benzoate HCl 0.01MpH 2
Stirring
700rpm
Room temperature
15min
Potentiometry
[122] Mebendazole PU
10mL
pH 9
No salt added
PP
8.8cm
0.6x0.2x0.2
1-undecanol HCl 100mMpH 1
Stirring
700rpm
Room temperature
60min
LC-UV
[122] Mebendazole PU
7mL
pH 1
No salt added
PP
8.8cm
0.6x0.2x0.2
NPOE HCl 100mMpH 1
Stirring
700rpm
Room temperature
150V
15min
LC-UV
[159] Ephedrine PU
7mL
pH 11
NaCl 12% (w/v)
PP
7.5cm
0.6x0.2x0.2
Toluene + 10% (w/v) TEHP HCl 1mMpH 3
Stirring
1200rpm
Room temperature
LC-UV
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25min
[159] Ephedrine PU
7mL
pH 2
PP
7.5cm
0.6x0.2x0.2
NPOE + 10% (v/v) DEHP HCl 100mMpH 1
Stirring
1000rpm
Room temperature
100V
15min
LC-UV
[189] Tramadol PU
pH 11
Ionic strength 4M
PP
10cm
0.6x0.2x0.2
1-dodecane Acetonitrile
Stirring
1000rpm
40min
GC-MS
[181] TrimipramineDesipramine
P
U
3mL
pH ca. 12
5% (w/v) NaCl
PP
1.3cm
0.6x0.2x0.2
1-dodecane Acetic acid 0.1MpH ca. 3
Stirring
860rpm
45oC
20min
ESI-IMS
[160] NaltrexoneNalmefene
P
U
pH 2
pH ca. 10
PP
5.6cm
0.6x0.2x0.2
NPOE + DEHP (85:15 v/v) HCl 100mMpH 1
Stirring
1250rpm
100V
20min
LC-UV
[123] Pentazocine PU
3mL
pH 9
No salt added
PP
1.3cm
0.6x0.2x0.2
1-octanol Acetic acid 0.5MpH ca. 3
Stirring
900rpm
20oC
25min
ESI-IMS
[201] Clomipramine PU
3mL
pH ca. 10
10% (w/v) NaCl
PP
3cm
0.6x0.2x0.2
1-dodecane Methanol
Stirring
1700rpm
20min
CD-IMS
[124]
Alfentanil
Fentanyl
Sufentanil
P
U
5mL
pH ca. 10
No salt added
PP
3.5cm
0.6x0.2x0.2
Isoamyl benzoate H2SO4 0.05MpH 1.3
Stirring
1200rpm
45oC
20min
LC-UV
[125] Amantadine PU
3mL
pH ca. 10
No salt added
PP
3cm
0.6x0.2x0.2
1-dodecane Methanol
Stirring
1400rpm
20min
CD-IMS
[126] Amphetamines U
3mL
pH 3
No salt added
PP
7cm
0.6x0.2x0.2
NPOE + 15% (v/v) TEHP HCl 100mMpH 1
Stirring
1000rpm
Room temperature
250V
7min
LC-UV
[127] Thebaine U
3mL
pH 3
No salt added
PP
6cm
0.6x0.2x0.2
NPOE HCl 100mMpH 1
Stirring
1250rpm
300V
15min
LC-UV
[99]
Atenolol
Betaxolol
Propranolol
OF
3mL
pH 3
No salt added
PP
6cm
0.6x0.2x0.2
NPOE + 10% (v/v) DEHP + 5% 
(v/v)  TEHP
HCl 100mM
pH 1
Stirring
1250rpm
250V
15min
LC-UV
[100] Levamisole
P
U
OF
4mL
pH 2
No salt added
PP
9cm
0.6x0.2x0.2
NPOE + 5% (v/v) TEHP HCl 100mMpH 1
Stirring
1000rpm
200V
15min
LC-UV
[169] AtropineScopolamine P pH 7.4
PP
10cm
0.55x0.45x0.18
1-heptanol:dimethyl benzene 
(30:70 v/v)
HCl 50mM
pH 1.3
No forced convection
37oC
5h
LC-UV
[128] Nimesulide P 5mLpH 2
PP
5.5cm Dihexyl ether
NaOH 20mM
pH 12.3
Stirring
400rpm LC-UV
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No salt added Room temperature (25oC)
30min
[129] Bisoprolol P
5.6mL
pH ca. 14
No salt added
PVDF
8.5cm
0.6x0.2x0.2
1-octanol Formic acid 1MpH 1.8
Stirring
800rpm
35oC
25min
LC-FD
[185] ImipramineClomipramine
P
U
2.1mL
pH 4
PP
2.6cm
0.6x0.2x0.2
NPOE pH 2
Stirring
1400rpm
200V
20min
GC-FID
[130] Diclofenac PU
2.1mL
pH 11
No salt added
PP
3.1cm
1.2x0.2x0.2
1-octanol NaOH 10mMpH 12
Stirring
1200rpm
30oC
20 V
5min
LC-UV
[90]
Butalbital
Secobarbital
Pentobarbital
Phenobarbital
B 1mLpH ca. 1
PP
9cm
0.6x0.2x0.2
Decanol NaOHpH 13
Sonication
5min GC-MS
[34] AMPAsMPA U
3mL
pH 1
30% (w/v) NaCl
PP
3cm
0.6x0.2x0.2
1-octanol NaOHpH 14
Stirring
600rpm
42oC
50min
LC-MS
[38] Methimazole PU
7.5mL
pH 12.2
CTAB 100mM
No salt added
PP
8.8cm
0.6x0.2x0.2
Octanol NaClO4 1.5M
Stirring
1250rpm
45oC
50min
LC-UV
[180] ChloropheniramineDextromethorphan P
7.5mL
pH 12.5
2% (w/v) NaCl
PP
8.8cm
0.6x0.2x0.2
Hexadecane HCl 0.5mMpH 3.3
Stirring
1250rpm
60min
LC-UV
[175] Basic drugs P 50µLpH 7.4
PP
3cm
0.6x0.2x0.2
3 fibers
NPOE Formic acid 10mMpH 2.9
No forced convection
200V
10min
LC-MS
[131] OfloxacinCiprofloxacin P
10mL
pH 8.5
No salt added
PP
8.8cm
0.6x0.2x0.2
1-octanol + 10% (w/v) Aliquat 336 pH 11mM NaCl
Stirring
1000rpm
45min
LC-UV
[132] Trimipamine PU
5mL
pH 4.5
No salt added
PP
8cm
0.6x0.2x0.2
NPOE pH 1
Stirring
1000rpm
51V
34min
CE-UV
[133]
Amitriptyline
Imipramine
Trimipramine
Clomipramine
P
U
5mL
pH 12
No salt added
PP
8cm
0.6x0.2x0.2
1-dodecane
Methanol +
0.01M HCl
pH 2
Stirring
1000rpm
40min
LC-UV
[134] Mitiglinide PU
10mL
pH 1.5
No salt added
PP
6cm
0.6x0.2x0.2
1-octanol NaOH 0.1MpH 13
Stirring
300rpm
Room temperature
45min
LC-UV
[135] Warfarin P
11mL
pH 2.3
No salt added
PP
8.8cm
0.6x0.2x0.2
1-octanol 0.1mM NaOHpH 11
Stirring
1000rpm
30min
LC-UV
[136] Apigenin U 11mL PP 1-octanol Carbonate 50mM Stirring LC-UV
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pH 3
No salt added
8.8cm
0.6x0.2x0.2
pH 11.5 1000rpm
Room temperature
75min
[137] Amlodipine PU
11mL
pH 13
No salt added
PP
8.8cm
0.6x0.2x0.2
Dibenzyl ether HCl 0.01MpH 2
Stirring
800rpm
Room temperature
45min
LC-UV
[91]
Cathinone
Amphetamines
Ketamine
DOI
B
HB 80µL
PP
5cm
0.6x0.2x0.2
ENB Acetic acid 10mMpH 3.4
No forced convection
15V
5min
LC-MS
[202] DextromethorphanPseudoephedrine
P
U
3mL
pH 12.7
0% and 30% (w/v) 
NaCl for 
dextromethorphan 
and 
pseudoephedrine
PP
3cm
0.6x0.2x0.2
1-dodecane Methanol
Stirring
750rpm
20min
CD-IMS
[138] HydroxyzineCetirizine P
10mL
pH 5  11
No salt added
PP
8.2cm
0.6x0.2x0.2
1-octanol pH 2
Stirring
1200rpm
Room temperature
30min and then 20min
CE-UV
[101] Amphetamines H
50mg
pH 14
1% (w/v) NaCl
PP
9cm
0.6x0.2x0.2
Dihexyl ether HCl 0.1MpH 1
Vibrating
1000rpm
45min
GC-MS
[139] Desipramine PU
3mL
pH ca. 13
No salt added
PP
0.8cm
0.6x0.2x0.2
1-dodecanol Methanol
Stirring
900rpm
Room temperature
25min
GC-NPD
[140] NalmefeneDiclofenac U
24mL
Neutral pH (6.5)
No salt added
PP
3.8cm
0.6x0.2x0.2
2 fibers
NPOE + 5% (v/v) DEHP
1-octanol
HCl 50mM
pH 1.3
NaOH 50mM
pH 12.7
Stirring
700rpm
40V
Room temperature
14min
LC-UV
[170]
Pethidine
Diphenhydramine
Nortriptyline
Methadone
U 1mLpH 12.6
PP
20mm
1.2x0.2x0.2
1-octanol HCl 10mMpH 2
Vibrating
1000rpm
30min
DESI-MS
[141] Sufentanil PU
4mL
pH 2.5
No salt added
PP
8cm
0.6x0.2x0.2
NPOE HCl 0.1M pH 1
Stirring
1000rpm
190V
28min
Voltametry
[161] Dexamethasone PU
7.5mL
pH 6
PP
3.3cm
0.6x0.2x0.2
1-octanol + 5% (w/v) Aliquat 336 NaClO4 0.65 MpH 10
Stirring
500rpm
80min
LC-UV
[142] Metformin PU
10mL
pH 13.4
PFBC 10mg
No salt added
PP
4cm
0.6x0.2x0.2
Dihexyl ether HCl 100mMpH 1
Stirring
300rpm
70oC
30min
LC-UV
[182] NSAID U
4mL
pH 3
10% (w/v) NaCl
PP
4cm
0.6x0.2x0.2
Dihexyl ether pH 13
Stirring
1500rpm
60oC
45min
LC-UV
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[143] Venlafaxine and metabolites P
4mL
pH 10
No salt added
PP
15cm
0.6x0.2x0.2
1-octanol Acetic acid 0.1MpH ca. 3
Stirring
1750rpm
20min
LC-MS/MS
[186] Tolterodine PU
3mL
pH 2
PP
8cm
0.6x0.2x0.2
NPOE HCl 500 mMpH 0.3
Stirring
1200rpm
54V
20oC
24min
CE-UV
[203] Ketoprofen P
5mL
pH 2
5% (w/v) NaCl
PP
8cm
0.6x0.2x0.2
1-octanol pH 11
Stirring
600rpm
Room temperature
30min
LC-UV
[155] Trimetazidine P
2.1mL
pH 14
250mM sodium
1-octanesulfonate
7% (w/v) Na2SO4
PP
10cm
0.6x0.2x0.2
1-octanol HCl 0.5MpH 0.3
Stirring
600rpm
25min
LC-UV
[102]
Butalbital
Secobarbital
Pentobarbital
Phenobarbital
L 1mLpH 1.1
PP
9cm
0.6x0.2x0.2
Eucalyptus oil NaOH 0.1MpH 13
Sonicating
5min GC-MS
[156] NSAID U pH 2
PP
13cm
0.6x0.2x0.2
Dihexyl ether pH 12
Stirring
300rpm
20min
CE-UV
[156] Sulfonamides U
50mL
pH 4
28% (w/v) Na2SO4 
PP
27cm
0.6x0.2x0.2
1-octanol pH 12
Stirring
300rpm
6h
LC-UV
LC-FD
[162] Morphine U 4mLpH 6
PP
8cm
0.6x0.2x0.2
NPOE + 10% (v/v) TEHP + 10% 
(v/v) DEHP
HCl 0.1M
pH 1
Stirring
1000rpm
90V
24min
DPV
[173]
Ketamine
Norketamine
Dehydronorketamine
U pH 1010% (w/v) NaCl
PP
7.5cm
0.6x0.2x0.2
Eucalyptus essential oil HCl 1 MpH 0
Vibrating
2400rpm
30min
GC-MS
[171] Pyrethroid and metabolites U
1.2mL
pH 4
Conc. HCl
8.3% (w/v) NaCl
PP
1cm
1.67x0.52x0.33
Dihexyl ether NaOH 0.1MpH 13 120min LC-UV
[92]
TCA
Desmethylclomipram
in
Fluoxetine
Norfluoxetine
B 4mLpH ca. 13
PP
8cm
0.6x0.2x0.2
Dodecane Formic acid 0.1MpH 2.4
Stirring
1200rpm
55oC
30min
GC-MS
[144] Dextromethorphan PU
4mL
pH 6
No salt added
PP
8cm
0.6x0.2x0.2
NPOE HCl 0.1MpH 1
Stirring
1000rpm
110V
20min
DPV
[145] Pramipexole PU
10mL
pH 11.5
No salt added
PP
4cm
0.6x0.2x0.2
1-octanol pH 3
Stirring
600rpm
25oC
40min
LC-UV
[146] MethamphetamineCocaine U
4mL
pH 6.5
PP
5cm
NPOE + 10% (v/v) DEHP + 10% 
(v/v) TEHP
pH 1
pH 12
Stirring
1000rpm CE-UV
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Methadone
Buprenorphine
Morphine
Ibuprofen
Ketoprofen
Enalapril
No salt added 0.6x0.2x0.2
4 fibers
1-octanol
1-octanol + 4% (w/v) CTAB
NPOE
50V
15min
[68] Atorvastatin U
24mL
pH 4
1.2% (w/v) NaCl
PP
8.5cm
0.6x0.2x0.2
1-octanol NaOH 0.001MpH 11
Stirring
1000rpm
60min
LC-UV
[147] Carbegoline PU
15mL
pH 10
No salt added
PP
8cm
0.6x0.2x0.2
1-octanol pH 3
Stirring
750rpm
Room temperature (25oC)
30min
LC-UV
[176] Aristolochic acid IAristolochic acid II P
4mL
pH 3
2% (w/v) NaCl
PP
6cm
0.6x0.2x0.2
1-octanol pH 11
Stirring (magnetofluid)
2000rpm
Room temperature (25oC)
8min
LC-FD
[148] BerberinePalmatine
P
U
3mL
pH 11.8
No salt added
PP
8cm
0.6x0.2x0.2
1-octanol HCl 0.1MpH 1
Stirring
600rpm
25oC
10min
CE-UV
[187] Propranolol PU
4mL
pH 3.5
PP
8cm
0.6x0.2x0.2
NPOE pH 1
Stirring
1250rpm
40V
20oC
32min
CE-UV
[191] THC-COOH U
1mL
pH < 3
1% (w/v) NaCl
PP
9cm
0.6x0.2x0.2
Dihexyl ether NaOH 0.1mMpH 10
Shaking
1200rpm
30min
GC-MS
[190]
Cocaine
Ketamine
Lidocaine
U
14mL
pH 11
20% (w/v) NaCl
PP
10cm
0.6x0.2x0.2
1-dodecane Acetonitrile
Stirring
700rpm
30min
GC-MS
[98] Lidocaine SeU
5mL
pH ca. 12
1% (w/v) KCl
PP
8.2cm
0.6x0.2x0.2
1-octanol HCl 0.01MpH ca. 2
Stirring
1000rpm
Room temperature
50min
LC-UV
[149] RosiglitazoneMetformin
P
U
10mL  10.7mL
pH 9  ca. 14
No salt added
No derivitizing agent 
 10mg/mL PFBC 
(100uL)
4cm Dihexyl ether HCl 0.1MpH 1
Stirring
300rpm
Room temperature  70oC
30 min+30min
LC-UV
[150] Citalopram U
4mL
pH 12.5
No salt added
PP
8.0cm
0.6x0.2x0.2
1-octanol pH 2.2
Stirring
1000rpm
28min
CE-UV
[70] Triamterene U
24mL
pH 14
11% (w/v) NaCl
PP
8.5cm
0.6x0.2x0.2
1-decanol pH 1
Stirring
800rpm
90min
LC-UV
[151] OlanzapineFluoxetine
U
P
3mL
pH 12
5% (w/v) NaCl
PP
2.8cm
1.2x0.2x0.2
1-octanol HCl 25 or 10mMpH 1.6 or 2
Stirring
1000rpm
60min
LC-UV
[151] OlanzapineFluoxetine
U
P
3mL
pH 6
PP
2.8cm NPPE
HCl 10mM
pH 2
Stirring
1000rpm LC-UV
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No salt added 1.2x0.2x0.2 200V
30min
[179] Benzodiazepines U
2mL
pH 10
10% (w/v) NaCl
PP
9cm
0.6x0.2x0.2
Dihexyl ether:1-nonanol (9:1 v/v) HCl 3MpH 0
Vibrating
2400rpm
90min
GC-MS
[152] DiclofenacNaproxen
U
P
4mL
pH 7.4
Triton X-100 0.2mM
No salt added
PP
6cm
0.6x0.2x0.2
1-octanol pH 12
Stirring
1000rpm
15V
15min
CE-UV
[188] Phenazopyridine UP
6.5mL
Neutral pH
PP
7.5cm
0.6x0.2x0.2
NPOE HCl 100mMpH 1
Stirring
1250rpm
100V
20min
LC-UV
[172] Atrazine and degradation products U
200mL
pH 7
20% (w/v) NaCl
PP
20cm
0.28x0.05x0.1
Dihexyl ether HCl 1MpH0
Stirring
150rpm
Room temperature (ca. 20)
5h
LC-UV
[183] Sitagliptin U
15mL
pH 10.5
35% (w/v) NaCl
PP
8.5cm
0.6x0.2x0.2
1-octanol pH 3
Stirring
1000rpm
25oC
50min
LC-UV
[153]
Atorvastatin
Lovastatin
Simvastatin
U
18mL
pH 2
No salt added
PP
10cm
0.6x0.2x0.2
1-dodecane + 5% (w/v) TOPO Methanol + NaOH 0.1MpH 13
Stirring
1000rpm
45min
LC-UV
GC-FID
[163] LevonogestrelMegestrol U
20mL
No pH adjustment
10% (w/v) NaCl
PP
8cm
0.6x0.2x0.2
1-dodecane + 5% (w/v) TOPO Methanol
Stirring
1000rpm
40min
LC-UV
[204] SSRI PU
6mL
pH 12.8
2% (w/v) NaCl
PP
3cm
0.6x0.2x0.2
Phenetole Acetic acid 0.1MpH ca. 3
Stirring
1000rpm
40min
Sweeping-
MEKC
[77] AlbendazoleTriclabendazole U
6mL
pH 8
No salt added
PP
8.8cm
0.6x0.2x0.2
1-undecanol 1-undecanol Vibrating3min LC-FD
[95]
Codeine
Naproxen
Ketamine
Ibuprofen
P
M
4mL
pH 6
PP
2.1cm
1.2x0.3x0.2
1-octanol (acidic)
2-ethyl hexanol (basic)
Stirring
750rpm
175V
25min
LC-UV
[95]
Codeine
Naproxen
Ketamine
Ibuprofen
P
M
4mL
pH 6
PP
2.1cm
1.2x0.3x0.2
1-octanol (acidic)
2-ethyl hexanol (basic)
HCl 32mM 
pH 1.5 (basic)
NaOH 32mM 
pH 12.5 (acidic)
Stirring
750rpm
150V 
6min 
400V 
19min
LC-UV
[154] Clozapine P
30mL
pH 4.5
No salt added
PP
10cm
1.2x0.3x0.2
NPOE pH 4.5
Stirring
1000rpm
200V
18min
Voltametry
[164] Nalidixic acid U 5mLpH ca. 12
PP
10cm
0.6x0.2x0.2
1-octanol + Aliquat 336 (9:1 v/v) NaCl 1M
Stirring
1000rpm
ca. 25oC
45min
LC-UV
[96] Ketamine (B)Codenie (B)
P
M
4mL
pH 6
PP
2.1cm
2-ethyl hexane (B)
1-octanol (A)
HCl pH 1.5 (B)
NaOH pH 12.5 (A)
Stirring
750rpm LC-UV
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Naproxene (A)
Ibuprofen (A)
1.2x0.3x0.2 150V 6min (A)  400V 
19min (B)
[104] Lamotrigine P
4mL
pH 9
No salt added
PP
15cm
0.6x0.2x0.2
1-octanol HCl pH 4
Stirring
500rpm
30min
Room T
CE-UV
[79] OxazepamLorazepam
U
P
25mL
No pH adjustment
PP
7cm
0.6x0.2x0.2
n-dodecane + TOPO 7.5% (w/v) Acetonitrile
Stirring
1000rpm
30min
LC-MS
[103]
Muscimol
Tryptophan
Tryptamine
U
10mL
pH 4
No salt added
PP
8cm
0.6x0.2x0.2
Dihexyl ether + DEHPA 20% 
(w/w) HCl 200mM
Stirring
800rpm
60min
LC-UV
[80] Triamterene U
24mL
NaOH 3M
2M NaCl
PP
8.5cm
0.6x0.2x0.2
1-decanol HCl pH 1
Stirring
800rpm
90min
LC-UV
[105] IbuprofenDiclofenac U
4mL
pH 10.5
No salt added
PP
6cm
0.6x0.2x0.2
1-octanol + 0.6% w/v C60 
fullerene NaOH pH 12.8
Stirring
1000rpm
28min
6V
LC-UV
[165] Bismuth P 5mL5mM H2SO4
PP
3.5cm
0.6x0.2x0.2
1-octanol + 1% (v/v) DEHP 300mM H2SO4
Stirring
700rpm
10min
70V
UV-Vis
[106] Diclofenac UP
0.05M HCl
No salt added
PP
2.5cm
0.6x0.2x0.2
n-dodecane Methanol
Stirring
1000rpm
20min
Room T
ESI-IMS
Table 3. 3-phase HF-LPME (and variants) of drugs of forensic interest in biological matrices. The concentration values of salt added were converted to % (w/v); 
the pH were calculated based on the concentration of base or acid in some cases. Abbreviations: (A) = acidic; Aliquat-336 = 3-caprylil methyl ammonium 
chloride; AMPAs = alkyl methylphosphonic acids; (B) = basic; B = whole blood; ca. = approximately; CE = capillary electrophoresis; DEHP = di-(2-ethylhexyl) 
phosphate; DOI = 2,5-dimethoxy-4-iodoamphetamine; FD = fluorescent detector; FDNB = 1-fluoro-2,4-dinitrobenzene; FIA = flow injection analysis; FID = flame 
ionization detector; GC = gas chromatography; H = hair; HB = haemolysed blood; id = internal diameter; L = liver; LC = high performance liquid chromatography; 
M = breast milk; MEKC = micellar electrokinetic chromatography; MPA = methylphosphonic acid; MS = mass spectrometry; MS/MS = tandem mass spectrometry; 
n.r. = not reported; Na2SO4 = sodium sulfate; NaCl = sodium chloride; NDCIT = N-desmethylcitalopram; NPD = nitrogen-phosphorus detector; NPOE = 2-
nitrophenyl octylether; OF = oral fluid; P = plasma; PP = polypropylene; ps = pore size; PVDF = polyvinylidene difluoride; Se = serum; SSRI = selective serotonin 
reuptake inhibitors; T = temperature; THC-COOH = 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid; TCA = tricyclic antidepressants; TEHP = tris(2-
ethylhexy)phosphate; TOPO = trioctylphosphine oxide; wt = wall thickness; U = urine; UV = ultra-violet; Vis = visible
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5. CONCLUSIONS
All the research related to new extraction methods, and specifically to HF-LPME, 
places this technique as a powerful method during sample preparation in bioanalysis. The 
increasing number of published articles during the years shows how acceptable HF-LPME 
has become in laboratories that perform analyses of biological material.
The advantages of HF-LPME over traditional extraction methods bring several 
benefits to numerous fields of toxicology, including forensic toxicology, and should facilitate 
complex sample handling. This review highlights that researchers concluded that HF-LPME 
is simple, fast and versatile. Moreover, the method presents a green-chemistry approach 
with high selectivity and enrichment. In addition to these advantages, the presence of the 
fiber assures the absence of carryover and helps to filter the sample, resulting in clean 
extracts.
On the other hand, many articles cited the difficulty of dealing with small volumes of 
solvents and of extracting many drugs simultaneously.
HF-LPME clearly presents a high application potential for routine testing in analytical 
toxicology laboratories. It’s potential for automation and its versatility regarding the suitability 
to different matrices and analytes place the technique in the bright list of methods with high 
potential to be adopted in forensic toxicology laboratories. By opening the new perspectives 
in sample preparation, the HF-LPME offers promising results for the field.
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Figure 1. Schematic representation of the HF-LPME device (A) and its photo (B) – by courtesy 
of 3M.
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Figure 2. Schematic representation of the mechanisms by which HF-LPME works. In the 2-
phase system, the lumen of the fiber is filled with the same organic solvent impregnated within 
the pores. In the 3-phase system, the lumen of the fiber is filled with a different solution 
responsible for accepting the analytes from the aqueous sample.
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Figure 3. Schematic representation of carrier-mediated HF-LPME mechanism. 
AH+ = ionized analyte; RCOO- = ionized carrier; RCOOH=non-ionized carrier. 
Adapted from [3, 39].
Figure 4. Schematic illustration of the equipment for EME
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Figure 5. Flowchart of the studies selection
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Table 1. Exclusion criteria applied to the review.
Ref. Analytes Matrix
Donor phase:
Volume
pH
Additives
Fiber:
Material
Length
id(mm)xwt(mm)xps(µm)
Solvent and Additives Acceptor phase and Additives Extraction process Instrumentation
[44] DiazepamPrazepam
U
P
1.5mL
pH 5.5
PP
4cm
0.6x0.2x0.2
1-octanol 1-octanol
Vibrating
1000rpm
30min
GC-NPD
[45] DiazepamNDMD
U
P
3.5 (U); 3.0mL (P)
pH 7.5
No salt added
PP
6cm
0.6x0.2x0.2
Butyl acetate:1-octanol (1:1 v/v) (U)
Dihexyl ether:1-octanol (1:3 v/v) (P)
Butyl acetate:1-octanol (1:1 v/v) 
(U)
Hexyl ether:1-octanol (1:3 v/v) (P)
Vibrating
600rpm
50min
GC-NPD
[46]
Cocaine
Cocaethylene
EMeE
AEME
U 8mLpH 10.6
PP
6cm
0.6x0.2x0.2
Chloroform Chloroform
Stirring
1600rpm
3min
GC-PDHID
[47] THC-COOH U
8mL
pH 8
Bu4N+-HSO4
PP
6cm
0.6x0.2x0.64
Octane:BSTFA (1:5 v/v) Octane:BSTFA (1:5 v/v)
Stirring
1540rpm
Room T
8min
GC-PDHID
[82]
Cocaine
Cocaethylene
EMeE
AEME
OF 2.2mLpH 10.5
PP
7cm
0.6x0.2x0.2
Chlorophorm Chlorophorm
Stirring
2000rpm
10min
GC-PDHID
[48]
Methadone
Promethazine
Haloperidol
U
P
4mL
pH 13.1
PP
8cm
0.6x0.2x0.2
Dihexyl ether Dihexyl ether
Vibrating
1500rpm
45min
GC-FID
[49] Mirtazapine P
4mL
pH 13.6
No salt added
PP
7cm
0.6x0.2x0.2
Toluene Toluene
Stirring
30min
ca. 22oC
LC-UV
[50] Basic drugs P pH 7
PP
6.5cm
0.6x0.2x0.2
1-octanol 1-octanol
Vibrating
1500rpm
60min
CE-UV
[51] Anabolic steroids U
4mL
pH 7
No salt added
PP
6cm
0.6xn.r.x0.2
1-octanol 1-octanol
Stirring
1250rpm
Room T
45min
LC-MS
[52]
Thiazide diuretics
Clopamide
Probenecid
Loop diuretics
U
7.5mL
pH 2
15% (w/v) NaCl
PP
8cm
0.6x0.2x0.2
1-octanol 1-octanol
Stirring
1010rpm
40oC
40min
LC-MS/MS
[53] Flunitrazepam PU
4mL
pH 9.5 (U); 8.0 (P)
No salt added
PVDF
1.8cm
1.2x0.2x0.2
p-xylene (U)
p-xylene:1-octanol (3:7 v/v) (P)
p-xylene (U)
p-xylene/1-octanol (3:7 v/v) (P)
Stirring
375 (P); 450 (U) rpm
30oC
30min
GC-MS/MS
[54]
Clenbuterol
Metoprolol
Propranolol
U
5mL
pH 12
14% (w/v) NaCl
PP
1.6cm
0.6x0.2x0.2
Methylbenzol Methylbenzol:MSTFA (1:1 v/v)
Stirring
925rpm
35oC
20min
GC-MS
[75] Free cyanide UOF
5mL
pH 6.5
Saturated with 
Na2SO4
Polyethersulfone
1.5cm
3.75x0.75x0.2
Sodium carbonate + Ni(II)-NH3
Sodium carbonate + Ni(II)-NH3
pH 11
Stirring
900rpm
Room T
10min
CE-UV
[83]
THC
CBD
CBN
H
10mg
pH 14
6.8% (w/v) NaCl
PP
6cm
0.6x0.2x0.2
Butyl acetate Butyl acetate
Stirring
600rpm
Room T
20min
GC-MS/MS
[55]
Promethazine
Promazine
Chlorpromazine
Trifluoperazine
U
3mL
pH 9
No salt added
PP
1.5cm
0.6x0.2x0.2
Toluene Toluene
Stirring
1000rpm
40oC
10min
GC-FPD
GC-FID
[5]
Amphetamines
Caffeine
Ketamine
U
3mL
pH 12.5
30% (w/v) NaCl
PP
1cm
0.6x0.2x0.2
o-xylene o-xylene
Stirring
1000rpm
Room T (30oC)
20min
GC-FID
[56] Pyrethroid metabolites U
5mL
pH ca. 1
PP
1.5, 2.0, 2.5 and 3.0cm
0.6x0.2x0.2
1-octanol 1-octanol
Stirring
70oC
10min
GC-ECD
[57]
Alfentanil
Fentanyl
Sufentanil
P
U
3mL
pH ca. 11
No salt added
PP
1cm
0.6x0.2x0.2
Dihexyl acetate Dihexyl acetate
Stirring
1000rpm
Room T (25oC)
15min
GC-NPD
[81]
Amitriptyline
Imipramine
Promethazine
B
30µL
pH 11
No salt added
PP
1cm
0.6x0.2x0.2
Toluene Toluene
Stirring
Room T
10min
GC-MS
[58] Tramadol PU
12mL
pH 12
No salt added
PP
1.5cm
n.r.
1-nonanol 1-nonanol
Stirring
1000rpm
Room T
25min
GC-MS
[59] Guaifenesin P
25mL
pH 7.4
1.7% (w/v) K2HPO4
PP
8cm
0.6x0.2x0.2
1-octanol 1-octanol
Stirring
600rpm
37oC
30min
LC-FD
[60] Anabolic steroids UH
20mL
No pH adjustment
7.5% (w/v) NaCl
PP
1.2cm
1.8x0.2x0.2
Toluene Toluene
Stirring
750rpm
40oC
30min
GC-MS
[61]
Imipramine
Desipramine
Citalopram
Sertraline
U 1.2mLNeutral (pH ca. 7)
PP
2.2cm
0.6x0.2x0.2
1-heptanol 1-heptanol
Stirring
1400rpm
60V
15min
GC-MS
[62] SulfetanilAlfentanil
P
U
5mL
pH 10
15% (w/v) NaCl 
PP
1.3cm
0.6x0.2x0.2
1-octanol 1-octanol
Stirring
700rpm
50oC
25min
GC-FID
[63] FluoxetineNorfluoxetine P
5mL
pH 11
No salt added
PP
3.7cm
0.6x0.2x0.2
Dihexyl ether Dihexyl ether
Vibrating
700rpm
30min
GC-MS
[64] Benzodiazepines PU
ca. 5 (P); ca. 25 (U) 
mL
pH ca. 9
No salt added
PP
10cm
0.6x0.2x0.2
Supramolecular solvent Supramolecular solvent
Stirring
900rpm
50min
LC-UV
[65]
Indomethacin
Dexamethasone
Propafenone
P
U
1.8ml
pH 2, 2-8, 10
20% (w/v) NaCl
PVDF
3.5cm
n.r.xn.r.xn.r.
1-octanol 1-octanol
Vibrating
173rpm
Room T
102, 120 and 102min
LC-UV
[66] Methadone PU
10mL
pH 11.5
5% (w/v) NaCl
PP
2cm
0.6x0.2x0.2
1-undecanol 1-undecanol
Stirring
700rpm
20oC
45min
GC-FID
[67] Nicotine P
4.5mL
pH 7.4
29% (w/v) NaCl
n.r.
3cm
n.r.
1-octanol 1-octanol
Sonicating
37oC
10min
GC-FID
[68] Amlodipine U
24mL
pH 10
1.2% (w/v) NaCl 
PP
8.5cm
0.6x0.2x0.2
1-octanol 1-octanol
Stirring
1000rpm
60min
LC-UV
[69]
Naloxone
Buprenorphine
Norbuprenorphine
P
5mL
pH 8.7
No salt added
PVDF
4cm
0.8x0.175x0.16
1-octanol:chlorophorm:toluene 
(2:4:4 v/v/v)
1-octanol:chlorophorm:toluene 
(2:4:4 v/v/v)
Stirring
1000rpm
20oC
30min
ULC-MS
[70] Hydrochlorothiazide U
24mL
pH 12
No salt added
PP
8.5cm
0.6x0.2x0.2
1-octanol  + 2% (w/v) Aliquat 336 1-octanol  + 2% (w/v) Aliquat 336
Stirring
800rpm
90min
LC-UV
[71]
Amphetamines
Methcatinone
Ketamine
Meperidine
Methadone
U
B
8mL
pH 13
PP
4cm
0.6x0.2x0.2
Toluene Toluene
Stirring
500rpm
30oC
15min
GC-MS
[72] Flunitrazepam PU
4mL
pH 9.5 (U); 8.0 (P)
No salt added
PVDF
1.8cm
1.2x0.2x0.2
p-xylene (U)
p-xylene:1-octanol (3:7 v/v) (P)
p-xylene (U)
p-xylene:1-octanol (3:7 v/v) (P)
Stirring
375 (P); 450 (U) rpm
30oC
30min
GC-MS
[73] Metamphetamine HU
4mL
pH 7
No salt added
PP
6cm
0.6x0.2x0.2
1-octanol + 2.5mg/mL grapheme oxide 1-octanol
Stirring
1000rpm
60V
20min
GC-FID
[74] Memantine P
10mL
pH 13
No salt added
PP
8cm
0.6x0.2x0.2
Cyclohexane
Cyclohexane + 0.3mg/mL dansyl 
chloride + 4% (v/v) triethylamine + 
10% (v/v) acetone
Stirring
800rpm
40oC
50min
LC-FD
[76] NaproxenNabumetone
P
U
pH 3
KCl 4% (w/v)
PP
4cm
0.6x0.2x0.2
1-undecanol 1-undecanol
Stirring
600rpm
45oC
20min
LC-FD
[77] AlbendazoleTriclabendazole U
pH 8
No salt added
PP
8.8cm
0.6x0.2x0.2
1-undecanol 1-undecanol
Vortexing
Room T
3min
LC-FD
[79] OxazepamLorazepam
U
P
25mL
No pH adjustment
7.5% (w/v) NaCl
PP
10cm
0.6x0.2x0.2
1-octanol 1-octanol
Stirring
1000rpm
50min
LC-MS
[80] HCTZ U
24mL
pH 12 
No salt added
PP
8.5cm
0.6x0.2x0.2
1-octanol + Aliquat 336 2% (w/w) 1-octanol + Aliquat 336 2% (w/w) Stirring800rpm
90min
LC-UV
[78] Warfarin P
8mL
pH 6.5
No salt added
PP
3cm
0.6x0.2x0.2
1-octanol + CTAB 10mM 1-octanol + CTAB 10mM
Stirring
800rpm
Room T
25min
UV-Vis
Table 2. 2-phase HF-LPME (conventional and variants) of drugs of forensic interest in biological matrices. The concentration values of salt added were converted 
to % (w/v); the pH were calculated based on the concentration of base or acid in some cases. Abbreviations: (A) = acidic; AEME = anhydroecgonine methyl 
ester; Aliquat-336 = 3-caprylil methyl ammonium chloride; (B) = basic; B = whole blood; BSTFA = bis(trimethylsilyl)trifluoroacetamide; Bu4N+-HSO4= tetra-n-
butylammonium; ca. = approximately; CBD = cannabidiol; CBN = cannabinol; CE = capillary electrophoresis; ECD = electron capture detector; EMeE = ecgonine 
methyl ester; FD = fluorescent detector; FID = flame ionization detector; FPD = flame photometric detector; GC = gas chromatography; H = hair; id = internal 
diameter; K2HPO4 = dipotassium phosphate; LC = high performance liquid chromatography; MS = mass spectrometry; MS/MS = tandem mass spectrometry; 
n.r. = not reported; Na2SO4 = sodium sulfate; NaCl = sodium chloride; NDMD = N-desmethyldiazepam; NPD = nitrogen-phosphorus detector; OF = oral fluid; P 
= plasma; PDHID = pulsed-discharge helium ionization detector-helium ionization detector; PP = polypropylene; ps = pore size; PVDF = polyvinylidene difluoride; 
T = temperature; THC-COOH = 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid; THC = Δ9-tetrahydrocannabinol; wt = wall thickness; U = urine; ULC = ultra-
high performance liquid chromatography; UV = ultra-violet
Ref. Analytes Matrix Donor phase
Fiber:
Material
Length
id(mm)xwt(mm)xps(µm
)
Solvent and Additives Acceptor phase and Additives Extraction process Instrumentation
[107] Methamphetamine UP
2.5mL
pH 13
No salt added
PP
8cm
0.6x0.2x0.2
1-octanol HCl 0.1MpH 1
Stirring
400rpm
45min
CE-UV
[192]
Ibuprofen
Naproxen
Ketoprofen
U 2.5mLpH 1
PP
8cm
0.6x0.2x0.2
Dihexyl ether NaOH 0.01mMpH 12
Vibrating
400rpm
45min
CE-UV
[44]
Metamphetamine 
(CE)
Naproxen (CE)
Citalopram (LC)
NDCIT (LC)
U
P
1-4mL
Variable pH
PP
4 or 8cm
0.6x0.2x0.2
1-octanol
HCl 0.1M (CE)
pH 1; 
NaOH 0.02M (LC)
pH 12.3
Vibrating
1000rpm
45min
CE-UV
LC-FD
[177] CitalopramNDCIT P
4mL
pH ca.13
PP
8cm
0.6x0.2x0.2
Dihexyl ether Phosphate buffer 20mMpH 2.75
Vibrating
1200rpm
60min
CE-UV
[85] MethamphetamineCitalopram
U
P
B
4mL
pH ca.13
PP
8cm
0.6x0.2x0.2
27cm
0.33x0.15x0.4
Dihexyl ether HCl 0.1MpH 1
Vibrating
1500rpm
15min (U, P); 30min (B)
CE-UV
[86] Amphetamines BU
1 (B); 4 (U)mL
pH ca. 13
PP
8cm
0.6x0.2x0.2
Dihexyl ether HCl 0.01MpH 2
Vibrating
1500rpm
15min
FIA-MS/MS
[193] Mianserin P 1mLpH ca. 13.5
PP
8cm
0.6x0.2x0.2
Dihexyl ether HCl 0.01MpH 2
Vibrating
1500rpm
45min
CE-UV
[48]
Methadone
Promethazine
Haloperidol
U
P
4mL
pH 13.1
PP
8cm
0.6x0.2x0.2
Dihexyl ether HCl 10mM
Vibrating
1500rpm
45min
CE-UV
[166] CitalopramDesmethylcitalopram P
1.5mL
pH ca. 13
PP
1.8cm
1.2x0.2x0.2
Dodecyl acetate Phosphate 20mMpH 2.75
Vibrating
1500rpm
45min
CE-UV
[93]
Paroxetine
Fluvoxamine
Mianserin
Citalopram
M 1.5mLpH ca. 13.5
PP
1.8cm
1.2x0.2x0.2
Polyphenyl-methylsiloxane HCl 10mMpH 2
Vibrating
1500rpm
60min
CE-UV
[87] Antidepressant drugs (TCA and SSRI)
P
B
1.5mL
pH 13.1
PP
1.8cm
1.2x0.2x0.2
Dodecyl acetate Formic acid 200mMpH ca. 2
Vibrating
 1500rpm
30min
LC-MS
CE-UV
[39]
Amphetamine
Morphine
Practolol
P
U
4mL
pH 7
Sodium octanoate
PP
8.0cm
0.6x0.2x0.2
1-octanol HCl 50mMpH 1.3
Vibrating
1500rpm
45min
CE-UV
[88] ZolpidemBenzodiazepines B
1.5mL
pH 7.5
PP
1.8cm
1.2x0.2x0.2
Nonanol HCl 0.4MpH 0.4
Vibrating
1500rpm
60min
LC-UV
LC-MS
[167]
Amphetamines
Pethidine
Nortriptyline
Methadone
P
U
1mL
pH ca. 13.5
PP
1.8cm
1.2x0.2x0.2
Plant fatty oils
Plant essential oils
Formic acid 10mM
pH 2.9
Vibrating
1200rpm
45min
CE-UV
Haloperidol
Loperamide
[157]
Amphetamine
Phenylpropanolamin
e
Cimetidine
Morphine
β-blockers
P
0.1mL
pH 7
Sodium octanoate
PP
6.5cm
0.6x0.2x0.2
1-octanol HCl 50mMpH 1.3
Vibrating
1500rpm
60min
LC-MS
[50] Basic drugs P
1.5mL
pH 13
Sodium octanoate
PP
1.8cm
1.2x0.2x0.2
Dodecyl acetate HCl 10mMpH 2
Vibrating
1500rpm
60min
CE-UV
[40]
Amphetamine
Phenylpropanolamin
e
Metaraminol
Cimetidine
Morphine
β-blockers 
P
0.1mL
pH 7
Bromothymol blue
PP
6.5cm
0.6x0.2x0.2
1-octanol or peppermint oil HCl 50mMpH 1.3
Vibrating
1500rpm
60min
CE-UV
[51] Steroids metabolite U n.r. n.r. Dihexyl ether
MSTFA:ammonium 
iodide:dithioerythritol 
(1000:2:4, v/m/m)
Stirring
1250rpm
45oC
30min
GC-MS
[194]
Imipramine
Amitriptyline
Setraline
P
U
11mL
pH 12
PP
8.8cm
0.6x0.2x0.2
1-dodecane H3PO4 0.1MpH 2.1
Stirring
700rpm
30min
LC-UV
[108] Clenbuterol U
7.5mL
pH 14
No salt added
PP
4.5cm
0.6x0.2x0.2
1-octanol Formic acid 5MpH 1.5
Stirring
1000rpm
30min
LC-UV
LC-MS/MS
[195] Hydroxychloroquine and metabolites U
ca. 4.3mL
pH ca.13
10% (w/v) NaCl
PP
7cm
0.6x0.2x0.2
1-octanol HCl 100mMpH 1
Stirring
1200rpm
Room temperature (ca. 
22oC)
40min
CE-UV
[97] Chlorpromazine USe
11mL
pH 11.8
No salt added
PP
8.8cm
0.6x0.2x0.2
1-dodecane HCl 0.01MpH 2
Stirring
1000rpm
Room temperature
20min
LC-UV
[109] StrychnineBrucine U
4mL
pH ca.13.5
No salt added
PP
8cm
0.6x0.2x0.2
1-octanol H3PO4 100mMpH 1.6
Stirring
1500rpm
Room temperature
40min
CE-UV
[110] TetradrineFangchinoline P
4.5mL
pH 8.5
No salt added
PP
7.5cm
0.6x0.2x0.2
1-octanol HCl 5mMpH 2.3
Stirring
1100rpm
Room temperature (ca. 
22oC)
60 min
LC-UV
[174] Mirtazapine and metabolites P
4mL
pH 8
15% (w/v) NaCl
PP
8cm
0.6x0.2x0.2
Dihexyl ether Acetic acid 0.01MpH 3.4
Sonicating
ca. 35oC
45min
LC-MS
[111] MefloquineCarboxymefloquine P
4mL
pH ca.13.5
No salt added
PP
6.5cm
0.6x0.2x0.2
Dihexyl ether HClO4 10mMpH 2
Stirring
1100rpm
Room temperature (ca. 
23oC)
LC-UV
30 min
[112] Chloroquine and metabolites P
4mL
pH 11
No salt added
PP
7cm
0.6x0.2x0.2
1-octanol TFA 0.1M
Stirring
1200rpm
Room temperature (ca. 
23oC)
30min
LC-MS/MS
[94]
Pethidine
Nortriptyline
Methadone
Haloperidol
Loperamide
P
U
M
1mL
pH 2
PP
2.5cm
1.2x0.2x0.2
1-isopropyl-4-nitrobenzene pH 2
Vibrating
1000rpm
10V
5min
CE-UV
[196] TCA P 1mLpH 10
PP
3.5cm
0.6x0.2x0.2
Dihexyl Ether
Sodium phosphate 
buffer 50mM
pH 3
Stirring
400rpm
45min
CE-UV
[113]
Furosemide
Bumetanide
Triamterene
U
6mL
pH 1.5 (for acidic)
pH 12.5 (for basic)
No salt added
PP
0.6x0.2x0.2 1-octanol
0.12M NaOH (for acidic)
pH 13.1
0.04M H3PO4 (for basic)
pH 1.9
Stirring
250rpm
Room temperature (ca. 
27oC)
50min
LC-UV
[111] MefloquineCarboxymefloquine P
4mL
pH ca. 12 then pH 
ca. 3
PP
15cm
0.6x0.2x0.2
Dihexyl ether
0.01M perchloric acid 
then 0.05M NaOH
pH 2 and 12.7
Vibrating
1750rpm
30min
LC-UV
[89]
Pethidine
Nortriptyline
Tramadol
Methadone
Haloperidol
Loperamide
P
B 0.5mL
PP
2.5cm
1.2x0.2x0.2
1-ethyl-2-nitrobenzene HCl 10mM
Vibrating
1050rpm
10V
10min
CE-UV
[197] Ibuprofen U 50mLpH 2
PP
27cm
0.6x0.2x0.2
Dihexyl ether NaOHpH 10
Stirring
300rpm
15min
FIA-CL
[198]
Ibuprofen
Diclofenac
Salicylic acid
U 50mLpH 2
PP
27cm
0.6x0.2x0.2
Dihexyl ether pH 12.5
Stirring
300rpm
15min
LC-UV
LC-FD
[158]
Oxytetracycline
Tetracycline
Doxycycline
P 11mLpH ca. 9
PP
8.8cm
0.6x0.2x0.2
1-octanol + 10% (w/v) Aliquat-336 0.1M H3PO4 + 1M NaCl pH 1.6
Stirring
900rpm
35min
LC-UV
[199] Pioglitazone PU
10mL
pH 8
10% (W/v) NaCl
PP
8.8cm
0.6x0.2x0.2
Dihexyl ether HClpH 2.2
Stirring
500rpm
30min
LC-UV
[114] Rosiglitazone PU
10mL
pH 9.5
No salt added
PP
6cm
0.6x0.2x0.2
Dihexyl ether HCl 0.1MpH 1
Stirring
600rpm
30min
CE-UV
LC-UV
[37] FluoxetineNorfluoxetine P
5mL
pH 14
No salt added
PP
7cm
0.6x0.2x0.2
Dihexyl ether HCl 20mMpH 1.7
Stirring
1400rpm
40min
LC-FD
[115] Gabapentin PU
8.5mL
No salt added
FDNB
PP
8.8cm
0.6x0.2x0.2
Dihexyl ether pH 9.1
Stirring
1250rpm
Room temperature
45min
LC-UV
[168]
Amitriptyline
Citalopram
Fluoxetine
P 70µLpH ca. 7.4
PP
2.9cm
1.2x0.2x0.2
1-ethyl-2-nitrobenzene HCOOH 10mMpH 2.9
No forced convection
9V
1min
LC-MS
Fluvoxamine
[36]
Ketoconazole
Clotrimazole
Miconazole
P
U
10mL
pH 11
NaCl 5% (w/v)
PP
8cm
0.6x0.2x0.2
Dihexyl ether pH 2.5
Stirring
800rpm
45min
LC-UV
[184] Amlodipine PU
3mL
pH 10
PP
8cm
0.6x0.2x0.2
NPOE HCl 10mMpH 2
Stirring
1000rpm
200V
15min
CE-UV
[116] Desipramine PU
8mL
pH 13
No salt added
PP
5cm
0.6x0.2x0.2
Propyl benzoate HCl 1MpH 0
Stirring
700rpm
Room temperature
15min
Voltametry
[117] Phenazopyridine PU
5mL
pH 9
No salt added
PP
3.5cm
0.6x0.2x0.2
Diphenyl ether H2SO4 0.1MpH 1
Stirring
1300rpm
45oC
30min
FIA-DAD
[200] Aristolochic acid U 5mLpH 3
PP
3.3cm
0.6x0.2x0.2
1-octanol NaOH 10mMpH 12
Stirring
800rpm
40min
LC-UV
[178]
Aconitine
Hypaconitine
Mesaconitine
U 5mLpH 11
PP
5.3cm
0.6x0.2x0.2
1-octanol HCl 10mMpH 3
Stirring
800rpm
40oC
60min
LC-UV
[118] MatrineSophocarpine U
4mL
pH 13.7
No salt added
PP
7cm
0.6x0.2x0.2
1-octanol H3PO4 100mMpH 1.5
Stirring
600rpm
60min
LC-UV
[35] ClotrimazoleMiconazole
P
U
24mL
pH 8
No salt added
PP
8cm
0.6x0.2x0.2
1-dodecane Acetonitrile
Stirring
900rpm
40min
GC-FID
[119] Propylthiouracil PU
7.5mL
pH 12
No salt added
PP
8.8cm
0.6x0.2x0.2
1-octanol + 6% (w/v) Aliquat 336 NaClO4 2MpH 9
Stirring
1250rpm
25oC
40min
LC-UV
[120] Dexamethasone PU
7.5mL
pH 3
No salt added
PP
8.8cm
0.6x0.2x0.2
1-octanol + 5% (w/v) Aliquat 336 NaClO4 2MpH 9
Stirring
1250rpm
Room temperature
60min
LC-UV
[121] Desipramine PU
8mL
pH 13
No salt added
PP
5cm
0.6x0.2x0.2
Propyl benzoate HCl 0.01MpH 2
Stirring
700rpm
Room temperature
15min
Potentiometry
[122] Mebendazole PU
10mL
pH 9
No salt added
PP
8.8cm
0.6x0.2x0.2
1-undecanol HCl 100mMpH 1
Stirring
700rpm
Room temperature
60min
LC-UV
[122] Mebendazole PU
7mL
pH 1
No salt added
PP
8.8cm
0.6x0.2x0.2
NPOE HCl 100mMpH 1
Stirring
700rpm
Room temperature
150V
15min
LC-UV
[159] Ephedrine PU
7mL
pH 11
NaCl 12% (w/v)
PP
7.5cm
0.6x0.2x0.2
Toluene + 10% (w/v) TEHP HCl 1mMpH 3
Stirring
1200rpm
Room temperature
LC-UV
25min
[159] Ephedrine PU
7mL
pH 2
PP
7.5cm
0.6x0.2x0.2
NPOE + 10% (v/v) DEHP HCl 100mMpH 1
Stirring
1000rpm
Room temperature
100V
15min
LC-UV
[189] Tramadol PU
pH 11
Ionic strength 4M
PP
10cm
0.6x0.2x0.2
1-dodecane Acetonitrile
Stirring
1000rpm
40min
GC-MS
[181] TrimipramineDesipramine
P
U
3mL
pH ca. 12
5% (w/v) NaCl
PP
1.3cm
0.6x0.2x0.2
1-dodecane Acetic acid 0.1MpH ca. 3
Stirring
860rpm
45oC
20min
ESI-IMS
[160] NaltrexoneNalmefene
P
U
pH 2
pH ca. 10
PP
5.6cm
0.6x0.2x0.2
NPOE + DEHP (85:15 v/v) HCl 100mMpH 1
Stirring
1250rpm
100V
20min
LC-UV
[123] Pentazocine PU
3mL
pH 9
No salt added
PP
1.3cm
0.6x0.2x0.2
1-octanol Acetic acid 0.5MpH ca. 3
Stirring
900rpm
20oC
25min
ESI-IMS
[201] Clomipramine PU
3mL
pH ca. 10
10% (w/v) NaCl
PP
3cm
0.6x0.2x0.2
1-dodecane Methanol
Stirring
1700rpm
20min
CD-IMS
[124]
Alfentanil
Fentanyl
Sufentanil
P
U
5mL
pH ca. 10
No salt added
PP
3.5cm
0.6x0.2x0.2
Isoamyl benzoate H2SO4 0.05MpH 1.3
Stirring
1200rpm
45oC
20min
LC-UV
[125] Amantadine PU
3mL
pH ca. 10
No salt added
PP
3cm
0.6x0.2x0.2
1-dodecane Methanol
Stirring
1400rpm
20min
CD-IMS
[126] Amphetamines U
3mL
pH 3
No salt added
PP
7cm
0.6x0.2x0.2
NPOE + 15% (v/v) TEHP HCl 100mMpH 1
Stirring
1000rpm
Room temperature
250V
7min
LC-UV
[127] Thebaine U
3mL
pH 3
No salt added
PP
6cm
0.6x0.2x0.2
NPOE HCl 100mMpH 1
Stirring
1250rpm
300V
15min
LC-UV
[99]
Atenolol
Betaxolol
Propranolol
OF
3mL
pH 3
No salt added
PP
6cm
0.6x0.2x0.2
NPOE + 10% (v/v) DEHP + 5% 
(v/v)  TEHP
HCl 100mM
pH 1
Stirring
1250rpm
250V
15min
LC-UV
[100] Levamisole
P
U
OF
4mL
pH 2
No salt added
PP
9cm
0.6x0.2x0.2
NPOE + 5% (v/v) TEHP HCl 100mMpH 1
Stirring
1000rpm
200V
15min
LC-UV
[169] AtropineScopolamine P pH 7.4
PP
10cm
0.55x0.45x0.18
1-heptanol:dimethyl benzene 
(30:70 v/v)
HCl 50mM
pH 1.3
No forced convection
37oC
5h
LC-UV
[128] Nimesulide P 5mLpH 2
PP
5.5cm Dihexyl ether
NaOH 20mM
pH 12.3
Stirring
400rpm LC-UV
No salt added Room temperature (25oC)
30min
[129] Bisoprolol P
5.6mL
pH ca. 14
No salt added
PVDF
8.5cm
0.6x0.2x0.2
1-octanol Formic acid 1MpH 1.8
Stirring
800rpm
35oC
25min
LC-FD
[185] ImipramineClomipramine
P
U
2.1mL
pH 4
PP
2.6cm
0.6x0.2x0.2
NPOE pH 2
Stirring
1400rpm
200V
20min
GC-FID
[130] Diclofenac PU
2.1mL
pH 11
No salt added
PP
3.1cm
1.2x0.2x0.2
1-octanol NaOH 10mMpH 12
Stirring
1200rpm
30oC
20 V
5min
LC-UV
[90]
Butalbital
Secobarbital
Pentobarbital
Phenobarbital
B 1mLpH ca. 1
PP
9cm
0.6x0.2x0.2
Decanol NaOHpH 13
Sonication
5min GC-MS
[34] AMPAsMPA U
3mL
pH 1
30% (w/v) NaCl
PP
3cm
0.6x0.2x0.2
1-octanol NaOHpH 14
Stirring
600rpm
42oC
50min
LC-MS
[38] Methimazole PU
7.5mL
pH 12.2
CTAB 100mM
No salt added
PP
8.8cm
0.6x0.2x0.2
Octanol NaClO4 1.5M
Stirring
1250rpm
45oC
50min
LC-UV
[180] ChloropheniramineDextromethorphan P
7.5mL
pH 12.5
2% (w/v) NaCl
PP
8.8cm
0.6x0.2x0.2
Hexadecane HCl 0.5mMpH 3.3
Stirring
1250rpm
60min
LC-UV
[175] Basic drugs P 50µLpH 7.4
PP
3cm
0.6x0.2x0.2
3 fibers
NPOE Formic acid 10mMpH 2.9
No forced convection
200V
10min
LC-MS
[131] OfloxacinCiprofloxacin P
10mL
pH 8.5
No salt added
PP
8.8cm
0.6x0.2x0.2
1-octanol + 10% (w/v) Aliquat 336 pH 11mM NaCl
Stirring
1000rpm
45min
LC-UV
[132] Trimipamine PU
5mL
pH 4.5
No salt added
PP
8cm
0.6x0.2x0.2
NPOE pH 1
Stirring
1000rpm
51V
34min
CE-UV
[133]
Amitriptyline
Imipramine
Trimipramine
Clomipramine
P
U
5mL
pH 12
No salt added
PP
8cm
0.6x0.2x0.2
1-dodecane
Methanol +
0.01M HCl
pH 2
Stirring
1000rpm
40min
LC-UV
[134] Mitiglinide PU
10mL
pH 1.5
No salt added
PP
6cm
0.6x0.2x0.2
1-octanol NaOH 0.1MpH 13
Stirring
300rpm
Room temperature
45min
LC-UV
[135] Warfarin P
11mL
pH 2.3
No salt added
PP
8.8cm
0.6x0.2x0.2
1-octanol 0.1mM NaOHpH 11
Stirring
1000rpm
30min
LC-UV
[136] Apigenin U 11mL PP 1-octanol Carbonate 50mM Stirring LC-UV
pH 3
No salt added
8.8cm
0.6x0.2x0.2
pH 11.5 1000rpm
Room temperature
75min
[137] Amlodipine PU
11mL
pH 13
No salt added
PP
8.8cm
0.6x0.2x0.2
Dibenzyl ether HCl 0.01MpH 2
Stirring
800rpm
Room temperature
45min
LC-UV
[91]
Cathinone
Amphetamines
Ketamine
DOI
B
HB 80µL
PP
5cm
0.6x0.2x0.2
ENB Acetic acid 10mMpH 3.4
No forced convection
15V
5min
LC-MS
[202] DextromethorphanPseudoephedrine
P
U
3mL
pH 12.7
0% and 30% (w/v) 
NaCl for 
dextromethorphan 
and 
pseudoephedrine
PP
3cm
0.6x0.2x0.2
1-dodecane Methanol
Stirring
750rpm
20min
CD-IMS
[138] HydroxyzineCetirizine P
10mL
pH 5  11
No salt added
PP
8.2cm
0.6x0.2x0.2
1-octanol pH 2
Stirring
1200rpm
Room temperature
30min and then 20min
CE-UV
[101] Amphetamines H
50mg
pH 14
1% (w/v) NaCl
PP
9cm
0.6x0.2x0.2
Dihexyl ether HCl 0.1MpH 1
Vibrating
1000rpm
45min
GC-MS
[139] Desipramine PU
3mL
pH ca. 13
No salt added
PP
0.8cm
0.6x0.2x0.2
1-dodecanol Methanol
Stirring
900rpm
Room temperature
25min
GC-NPD
[140] NalmefeneDiclofenac U
24mL
Neutral pH (6.5)
No salt added
PP
3.8cm
0.6x0.2x0.2
2 fibers
NPOE + 5% (v/v) DEHP
1-octanol
HCl 50mM
pH 1.3
NaOH 50mM
pH 12.7
Stirring
700rpm
40V
Room temperature
14min
LC-UV
[170]
Pethidine
Diphenhydramine
Nortriptyline
Methadone
U 1mLpH 12.6
PP
20mm
1.2x0.2x0.2
1-octanol HCl 10mMpH 2
Vibrating
1000rpm
30min
DESI-MS
[141] Sufentanil PU
4mL
pH 2.5
No salt added
PP
8cm
0.6x0.2x0.2
NPOE HCl 0.1M pH 1
Stirring
1000rpm
190V
28min
Voltametry
[161] Dexamethasone PU
7.5mL
pH 6
PP
3.3cm
0.6x0.2x0.2
1-octanol + 5% (w/v) Aliquat 336 NaClO4 0.65 MpH 10
Stirring
500rpm
80min
LC-UV
[142] Metformin PU
10mL
pH 13.4
PFBC 10mg
No salt added
PP
4cm
0.6x0.2x0.2
Dihexyl ether HCl 100mMpH 1
Stirring
300rpm
70oC
30min
LC-UV
[182] NSAID U
4mL
pH 3
10% (w/v) NaCl
PP
4cm
0.6x0.2x0.2
Dihexyl ether pH 13
Stirring
1500rpm
60oC
45min
LC-UV
[143] Venlafaxine and metabolites P
4mL
pH 10
No salt added
PP
15cm
0.6x0.2x0.2
1-octanol Acetic acid 0.1MpH ca. 3
Stirring
1750rpm
20min
LC-MS/MS
[186] Tolterodine PU
3mL
pH 2
PP
8cm
0.6x0.2x0.2
NPOE HCl 500 mMpH 0.3
Stirring
1200rpm
54V
20oC
24min
CE-UV
[203] Ketoprofen P
5mL
pH 2
5% (w/v) NaCl
PP
8cm
0.6x0.2x0.2
1-octanol pH 11
Stirring
600rpm
Room temperature
30min
LC-UV
[155] Trimetazidine P
2.1mL
pH 14
250mM sodium
1-octanesulfonate
7% (w/v) Na2SO4
PP
10cm
0.6x0.2x0.2
1-octanol HCl 0.5MpH 0.3
Stirring
600rpm
25min
LC-UV
[102]
Butalbital
Secobarbital
Pentobarbital
Phenobarbital
L 1mLpH 1.1
PP
9cm
0.6x0.2x0.2
Eucalyptus oil NaOH 0.1MpH 13
Sonicating
5min GC-MS
[156] NSAID U pH 2
PP
13cm
0.6x0.2x0.2
Dihexyl ether pH 12
Stirring
300rpm
20min
CE-UV
[156] Sulfonamides U
50mL
pH 4
28% (w/v) Na2SO4 
PP
27cm
0.6x0.2x0.2
1-octanol pH 12
Stirring
300rpm
6h
LC-UV
LC-FD
[162] Morphine U 4mLpH 6
PP
8cm
0.6x0.2x0.2
NPOE + 10% (v/v) TEHP + 10% 
(v/v) DEHP
HCl 0.1M
pH 1
Stirring
1000rpm
90V
24min
DPV
[173]
Ketamine
Norketamine
Dehydronorketamine
U pH 1010% (w/v) NaCl
PP
7.5cm
0.6x0.2x0.2
Eucalyptus essential oil HCl 1 MpH 0
Vibrating
2400rpm
30min
GC-MS
[171] Pyrethroid and metabolites U
1.2mL
pH 4
Conc. HCl
8.3% (w/v) NaCl
PP
1cm
1.67x0.52x0.33
Dihexyl ether NaOH 0.1MpH 13 120min LC-UV
[92]
TCA
Desmethylclomipram
in
Fluoxetine
Norfluoxetine
B 4mLpH ca. 13
PP
8cm
0.6x0.2x0.2
Dodecane Formic acid 0.1MpH 2.4
Stirring
1200rpm
55oC
30min
GC-MS
[144] Dextromethorphan PU
4mL
pH 6
No salt added
PP
8cm
0.6x0.2x0.2
NPOE HCl 0.1MpH 1
Stirring
1000rpm
110V
20min
DPV
[145] Pramipexole PU
10mL
pH 11.5
No salt added
PP
4cm
0.6x0.2x0.2
1-octanol pH 3
Stirring
600rpm
25oC
40min
LC-UV
[146] MethamphetamineCocaine U
4mL
pH 6.5
PP
5cm
NPOE + 10% (v/v) DEHP + 10% 
(v/v) TEHP
pH 1
pH 12
Stirring
1000rpm CE-UV
Methadone
Buprenorphine
Morphine
Ibuprofen
Ketoprofen
Enalapril
No salt added 0.6x0.2x0.2
4 fibers
1-octanol
1-octanol + 4% (w/v) CTAB
NPOE
50V
15min
[68] Atorvastatin U
24mL
pH 4
1.2% (w/v) NaCl
PP
8.5cm
0.6x0.2x0.2
1-octanol NaOH 0.001MpH 11
Stirring
1000rpm
60min
LC-UV
[147] Carbegoline PU
15mL
pH 10
No salt added
PP
8cm
0.6x0.2x0.2
1-octanol pH 3
Stirring
750rpm
Room temperature (25oC)
30min
LC-UV
[176] Aristolochic acid IAristolochic acid II P
4mL
pH 3
2% (w/v) NaCl
PP
6cm
0.6x0.2x0.2
1-octanol pH 11
Stirring (magnetofluid)
2000rpm
Room temperature (25oC)
8min
LC-FD
[148] BerberinePalmatine
P
U
3mL
pH 11.8
No salt added
PP
8cm
0.6x0.2x0.2
1-octanol HCl 0.1MpH 1
Stirring
600rpm
25oC
10min
CE-UV
[187] Propranolol PU
4mL
pH 3.5
PP
8cm
0.6x0.2x0.2
NPOE pH 1
Stirring
1250rpm
40V
20oC
32min
CE-UV
[191] THC-COOH U
1mL
pH < 3
1% (w/v) NaCl
PP
9cm
0.6x0.2x0.2
Dihexyl ether NaOH 0.1mMpH 10
Shaking
1200rpm
30min
GC-MS
[190]
Cocaine
Ketamine
Lidocaine
U
14mL
pH 11
20% (w/v) NaCl
PP
10cm
0.6x0.2x0.2
1-dodecane Acetonitrile
Stirring
700rpm
30min
GC-MS
[98] Lidocaine SeU
5mL
pH ca. 12
1% (w/v) KCl
PP
8.2cm
0.6x0.2x0.2
1-octanol HCl 0.01MpH ca. 2
Stirring
1000rpm
Room temperature
50min
LC-UV
[149] RosiglitazoneMetformin
P
U
10mL  10.7mL
pH 9  ca. 14
No salt added
No derivitizing agent 
 10mg/mL PFBC 
(100uL)
4cm Dihexyl ether HCl 0.1MpH 1
Stirring
300rpm
Room temperature  70oC
30 min+30min
LC-UV
[150] Citalopram U
4mL
pH 12.5
No salt added
PP
8.0cm
0.6x0.2x0.2
1-octanol pH 2.2
Stirring
1000rpm
28min
CE-UV
[70] Triamterene U
24mL
pH 14
11% (w/v) NaCl
PP
8.5cm
0.6x0.2x0.2
1-decanol pH 1
Stirring
800rpm
90min
LC-UV
[151] OlanzapineFluoxetine
U
P
3mL
pH 12
5% (w/v) NaCl
PP
2.8cm
1.2x0.2x0.2
1-octanol HCl 25 or 10mMpH 1.6 or 2
Stirring
1000rpm
60min
LC-UV
[151] OlanzapineFluoxetine
U
P
3mL
pH 6
PP
2.8cm NPPE
HCl 10mM
pH 2
Stirring
1000rpm LC-UV
No salt added 1.2x0.2x0.2 200V
30min
[179] Benzodiazepines U
2mL
pH 10
10% (w/v) NaCl
PP
9cm
0.6x0.2x0.2
Dihexyl ether:1-nonanol (9:1 v/v) HCl 3MpH 0
Vibrating
2400rpm
90min
GC-MS
[152] DiclofenacNaproxen
U
P
4mL
pH 7.4
Triton X-100 0.2mM
No salt added
PP
6cm
0.6x0.2x0.2
1-octanol pH 12
Stirring
1000rpm
15V
15min
CE-UV
[188] Phenazopyridine UP
6.5mL
Neutral pH
PP
7.5cm
0.6x0.2x0.2
NPOE HCl 100mMpH 1
Stirring
1250rpm
100V
20min
LC-UV
[172] Atrazine and degradation products U
200mL
pH 7
20% (w/v) NaCl
PP
20cm
0.28x0.05x0.1
Dihexyl ether HCl 1MpH0
Stirring
150rpm
Room temperature (ca. 20)
5h
LC-UV
[183] Sitagliptin U
15mL
pH 10.5
35% (w/v) NaCl
PP
8.5cm
0.6x0.2x0.2
1-octanol pH 3
Stirring
1000rpm
25oC
50min
LC-UV
[153]
Atorvastatin
Lovastatin
Simvastatin
U
18mL
pH 2
No salt added
PP
10cm
0.6x0.2x0.2
1-dodecane + 5% (w/v) TOPO Methanol + NaOH 0.1MpH 13
Stirring
1000rpm
45min
LC-UV
GC-FID
[163] LevonogestrelMegestrol U
20mL
No pH adjustment
10% (w/v) NaCl
PP
8cm
0.6x0.2x0.2
1-dodecane + 5% (w/v) TOPO Methanol
Stirring
1000rpm
40min
LC-UV
[204] SSRI PU
6mL
pH 12.8
2% (w/v) NaCl
PP
3cm
0.6x0.2x0.2
Phenetole Acetic acid 0.1MpH ca. 3
Stirring
1000rpm
40min
Sweeping-
MEKC
[77] AlbendazoleTriclabendazole U
6mL
pH 8
No salt added
PP
8.8cm
0.6x0.2x0.2
1-undecanol 1-undecanol Vibrating3min LC-FD
[95]
Codeine
Naproxen
Ketamine
Ibuprofen
P
M
4mL
pH 6
PP
2.1cm
1.2x0.3x0.2
1-octanol (acidic)
2-ethyl hexanol (basic)
Stirring
750rpm
175V
25min
LC-UV
[95]
Codeine
Naproxen
Ketamine
Ibuprofen
P
M
4mL
pH 6
PP
2.1cm
1.2x0.3x0.2
1-octanol (acidic)
2-ethyl hexanol (basic)
HCl 32mM 
pH 1.5 (basic)
NaOH 32mM 
pH 12.5 (acidic)
Stirring
750rpm
150V 
6min 
400V 
19min
LC-UV
[154] Clozapine P
30mL
pH 4.5
No salt added
PP
10cm
1.2x0.3x0.2
NPOE pH 4.5
Stirring
1000rpm
200V
18min
Voltametry
[164] Nalidixic acid U 5mLpH ca. 12
PP
10cm
0.6x0.2x0.2
1-octanol + Aliquat 336 (9:1 v/v) NaCl 1M
Stirring
1000rpm
ca. 25oC
45min
LC-UV
[96] Ketamine (B)Codenie (B)
P
M
4mL
pH 6
PP
2.1cm
2-ethyl hexane (B)
1-octanol (A)
HCl pH 1.5 (B)
NaOH pH 12.5 (A)
Stirring
750rpm LC-UV
Naproxene (A)
Ibuprofen (A)
1.2x0.3x0.2 150V 6min (A)  400V 
19min (B)
[104] Lamotrigine P
4mL
pH 9
No salt added
PP
15cm
0.6x0.2x0.2
1-octanol HCl pH 4
Stirring
500rpm
30min
Room T
CE-UV
[79] OxazepamLorazepam
U
P
25mL
No pH adjustment
PP
7cm
0.6x0.2x0.2
n-dodecane + TOPO 7.5% (w/v) Acetonitrile
Stirring
1000rpm
30min
LC-MS
[103]
Muscimol
Tryptophan
Tryptamine
U
10mL
pH 4
No salt added
PP
8cm
0.6x0.2x0.2
Dihexyl ether + DEHPA 20% 
(w/w) HCl 200mM
Stirring
800rpm
60min
LC-UV
[80] Triamterene U
24mL
NaOH 3M
2M NaCl
PP
8.5cm
0.6x0.2x0.2
1-decanol HCl pH 1
Stirring
800rpm
90min
LC-UV
[105] IbuprofenDiclofenac U
4mL
pH 10.5
No salt added
PP
6cm
0.6x0.2x0.2
1-octanol + 0.6% w/v C60 
fullerene NaOH pH 12.8
Stirring
1000rpm
28min
6V
LC-UV
[165] Bismuth P 5mL5mM H2SO4
PP
3.5cm
0.6x0.2x0.2
1-octanol + 1% (v/v) DEHP 300mM H2SO4
Stirring
700rpm
10min
70V
UV-Vis
[106] Diclofenac UP
0.05M HCl
No salt added
PP
2.5cm
0.6x0.2x0.2
n-dodecane Methanol
Stirring
1000rpm
20min
Room T
ESI-IMS
Table 3. 3-phase HF-LPME (and variants) of drugs of forensic interest in biological matrices. The concentration values of salt added were converted to % (w/v); 
the pH were calculated based on the concentration of base or acid in some cases. Abbreviations: (A) = acidic; Aliquat-336 = 3-caprylil methyl ammonium 
chloride; AMPAs = alkyl methylphosphonic acids; (B) = basic; B = whole blood; ca. = approximately; CE = capillary electrophoresis; DEHP = di-(2-ethylhexyl) 
phosphate; DOI = 2,5-dimethoxy-4-iodoamphetamine; FD = fluorescent detector; FDNB = 1-fluoro-2,4-dinitrobenzene; FIA = flow injection analysis; FID = flame 
ionization detector; GC = gas chromatography; H = hair; HB = haemolysed blood; id = internal diameter; L = liver; LC = high performance liquid chromatography; 
M = breast milk; MEKC = micellar electrokinetic chromatography; MPA = methylphosphonic acid; MS = mass spectrometry; MS/MS = tandem mass spectrometry; 
n.r. = not reported; Na2SO4 = sodium sulfate; NaCl = sodium chloride; NDCIT = N-desmethylcitalopram; NPD = nitrogen-phosphorus detector; NPOE = 2-
nitrophenyl octylether; OF = oral fluid; P = plasma; PP = polypropylene; ps = pore size; PVDF = polyvinylidene difluoride; Se = serum; SSRI = selective serotonin 
reuptake inhibitors; T = temperature; THC-COOH = 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid; TCA = tricyclic antidepressants; TEHP = tris(2-
ethylhexy)phosphate; TOPO = trioctylphosphine oxide; wt = wall thickness; U = urine; UV = ultra-violet; Vis = visible
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